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Abstract 
 
Heart failure is a major cardiovascular disease state and an increasing burden on our society 
and health care budget. Following a myocardial infarction there is an increase in 
inflammatory cytokine levels in the brain. This occurs within 30 minutes of a myocardial 
infarction. The increase in cytokines may result from (i) peripherally produced cytokines 
being transported across the blood brain barrier, and (ii) local production, as mRNA levels of 
pro-inflammatory cytokines are elevated. This local production could involve the immune 
cells of the brain. Microglia are the primary immune cells in the brain and when activated 
they secrete cytokines thereby potentially contributing to the local elevation in pro-
inflammatory cytokines. A recent study showed that 2-5 weeks following a myocardial 
infarction, microglia become activated within the hypothalamic paraventricular nucleus 
(PVN). It is not known whether microglia are activated earlier. Furthermore, it is not known 
whether activation of microglia is limited to the PVN, or if inhibiting the microglial 
activation influences local neuronal function and cardiac function.  
 
The first study in the work aimed to investigate the time course of activated microglia 
following a myocardial infarction. To investigate the time course of activated microglia, 
Sprague-Dawley rats were sacrificed at 24 hours, 1, 4, 8, 12 or 16 weeks following a 
myocardial infarction. The hypothalamus was cut and processed immunohistochemically to 
detect the microglial marker CD11b (clone OX-42). The presence of this marker together 
with morphological changes of the microglia was used to identify activated microglia. 
Compared to control rats, there was a significant increase in activated microglia in the PVN 
at 4, 8, 12 and 16 weeks after the MI.  
2 
 
No significant difference from control rats was observed at 24 hours or 1 week post MI. 
There was no correlation found between the echocardiography measures of heart function and 
the proportion of activated microglia. 
 
 
The second study in this thesis investigated (i) whether microglia become activated in 
cardioregulatory areas of the brain other than the PVN, (ii) whether activation of neurons 
occurs in those regions, and (iii) whether we can inhibit microglial activation and if that 
changes neuronal activation or improves cardiac function. This study used rats 12 weeks post 
myocardial infarction. In order to determine what effect microglia were having following 
myocardial infarction, rats were infused with either minocycline or saline into the lateral 
ventricle. The brains were collected and processed immunohistochemically to detect the 
microglial marker CD11b (clone OX-42) as well as a marker of neuronal activation, Fos 
related antigen (FRA).  
 
At 12 weeks following a myocardial infarction there was a significant increase in microglial 
activation within the paraventricular neucleus (PVN), periaquaducal grey (PAG), rostro 
ventral lateral medulla  (RVLM), nucleus tract solitarus (NTS) and area postrema (AP). 
Minocycline treatment was able to reduce the microglial activation in these areas by 10-50%. 
At 12 weeks following a myocardial infarction there was a significant increase in neuronal 
activation within the PVN, PAG, RVLM and NTS, which minocycline treatment was able to 
drastically reduce.  However no improvement in cardiac function was observed.  
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In conclusion following MI, microglia are activated within the PVN, RVLM and NTS. This 
may contribute to the increase in neuronal activation as decreasing microglial activation 
reduced neuronal activation. However a reduction in microglial activation did not improve 
cardiac function suggesting inflammation in those cardiovascular areas of the brain are not 
playing a key role in cardiac function. This does not preclude these areas from influencing 
other cardiovascular functions which needs to be further investigated. 
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Abbreviations 
tumour necrosis factor-α         TNF-α 
interleukin 1-β          IL-1β  
interleukin-6           IL-6 
C-reactive protein          CRP 
studies on left ventricular dysfunction       SOLVD 
cyclooxygenase-2          COX-2 
prostaglandin E2          PGE2 
organum vasculosum laminae terminalis       OVLT 
paraventricular nucleus        PVN 
cardiac sympathetic afferent reflex        CSAR 
Supraoptic nucleus          SON 
nucleus of the solitary tract         NTS 
periaquiductal grey          PAG 
D,L-Homocysteic acid         DLH 
gamma-amnio butyric acid         GABA 
left ventricular end diastolic pressure       LVEDP 
sympathetic nerve activity         SNA 
intermediolateral nucleus         IML 
angiotensin ІІ          Ang ІІ 
angiotensin receptor type 1         AT1 
adenosin triphosphate         ATP 
nucleus ambiguous          NA 
dorsal motor nucleus of the vagus nerve       DMNV 
cerebral spinal fluid          CSF 
specific pathogen free         SPF 
left anterior descending coronary artery       LAD 
subcutanious           s.c 
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ejection fraction          EF 
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stroke volume          SV 
intra-ventricular septal thickness in systole       IVSs 
intra-ventricular septal thickness in diastole       IVSd 
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left ventricular internal diameter in systole       LVIDs 
left ventricular internal diameter in diastole       LVIDd 
left ventricular posterior wall thickness in systole      LVPWs 
left ventricular posterior wall thickness in diastole      LVPWd 
end-diastolic volume          EDV 
end-systolic volume          ESV 
intra-venous           i.v 
phosphate buffered saline         PBS 
normal horse serum          NHS 
3,3`-diaminobenzidine hydrochloride       DAB 
hydrogen peroxide         H2O2 
analysis of variance          ANOVA 
optic tract           OT 
spinal trigeminal tract         STN 
inferior olivary nucleus         ION 
pyramidal tracts          Pry 
intra-peritonial          i.p 
fornix            Fx 
3rd ventricle           3V 
standard error of the mean         SEM 
renal sympathetic nerve activity        RSNA 
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Chapter 1: Introduction 
 
Ventricular dysfunction and heart failure are conditions that have a large impact on today’s 
society and this is expected to increase given the aging population. A major cause for these 
conditions is myocardial infarction. Immediately following myocardial infarction there are 
changes that occur including decreased stroke volume and reduced cardiac output, for which 
the body tries to compensate. However these compensatory actions ultimately add more 
strain on the remaining heart tissue and contributes to the progressive deterioration of heart 
function.  
 
One of the physiological responses seen following myocardial infarction is an increase in 
cytokines in the blood and cardiac tissue, and there is a direct correlation between blood 
cytokine levels and severity of heart failure. Increased levels of cytokines are also observed 
in the central nervous system following myocardial infarction. Various hypotheses have been 
suggested to explain how cytokines can be present in the brain as they don’t readily cross the 
blood brain barrier. One possibility is local production from microglia, which are the resident 
immune cells in the brain, and can release cytokines when activated. Therefore a key focus of 
the present research was to investigate microglia within key cardiovascular regulatory areas 
of the brain, since the autonomic changes seen in heart failure could originate from those key 
areas within the brain.  
 
 
 
7 
 
Section 1.1: Heart Failure 
 
Heart failure is a condition where the heart is unable to pump sufficient blood around the 
body to meet the body’s needs. It usually develops slowly and over many years with 
progressive reduction of ventricular function.  People with severe heart failure often have 
chronic tiredness, reduced capacity for exercise and a shortness of breath and a poor 
prognosis. In Australia there is an estimated 300,000 people with chronic heart failure and 
approximately 30,000 new cases are diagnosed each year with this condition. The impact on 
the healthcare system is considerable (Field, 2003). The risk factors associated with heart 
failure include congenital heart defects, high blood pressure, diabetes, obesity and diseases of 
the heart muscle or valves such as cardiomyopathy or myocarditis. Many of these risk factors 
are on the rise and the incidence of heart failure is likewise expected to increase (Field, 
2003). The most common cause of heart failure is myocardial infarction.  
 
Section 1.2: Myocardial Infarction 
 
Following a myocardial infarction there are a number of physiological responses that can be 
detrimental to the patient. As a direct result of damage done to the heart during a myocardial 
infarction there are cardiac changes which result in decreased stroke volume, reduced cardiac 
output, increased end-diastolic pressure, impaired filling of the ventricle (diastolic 
dysfunction) and reduced ejection fraction (systolic dysfunction). To compensate for these 
effects the heart undergoes cardiac remodelling and there is an increase in sympathetic nerve 
activity. The elevation in sympathetic nerve activity increases the rate and force with which 
the heart contracts. In the short term this is beneficial. However, these changes become 
detrimental in the long term. For example, an increase in cardiac sympathetic nerve activity 
may cause abnormal calcium cycling. Changes in calcium cycling increase the likelihood of 
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spontaneous depolarization, arrhythmia development and sudden death (Reiken et al., 2001, 
Lehnart et al., 2004). In heart failure there is also an increased sympathetic nerve activity to 
the kidneys which exacerbates heart failure due to impaired kidney function and fluid 
retention (Kaye et al., 1995, Keating and Sanguinetti, 2001). This in turn increases blood 
volume putting even more strain on the damaged heart.  
 
Section 1.3: Myocardial Infarction and Inflammation 
 
A myocardial infarction can cause widespread damage to the heart tissue. In response to that 
damage the immune system becomes activated and there is an increase in proinflammatory 
cytokines. The triggers for proinflammatory cytokine release immediately following 
myocardial infarction include mechanical deformation, ischemia, reactive oxygen species and 
cytokine self-amplification pathways (Nian et al., 2004). Within the first few hours post 
myocardial infarction cytokines such as tumour necrosis factor-α (TNF-α), interleukin 1-β 
(IL-1β) and interleukin-6 (IL-6) mRNA expression increased up to 50-fold in the infarct area 
and up to 15-fold in the non-infarcted myocardium (Irwin et al., 1999, Deten et al., 2002). 
This up-regulation will return to baseline if the infarct is small, however, with large 
infarctions there is a sustained cytokine up-regulation. This can be seen in several clinical 
studies showing that serum levels of TNF-α, IL-6 and C-reactive protein (CRP) are elevated 
in patients with chronic heart failure (Levine et al., 1990, Munger et al., 1996, Torre-Amione 
et al., 1996, Aukrust et al., 1999).  
 
Since the 1990’s it has been established that increases in the plasma levels of 
proinflammatory cytokines correlate with poor cardiac function and patient survival (Levine 
et al., 1990, Testa et al., 1996, Maeda et al., 2000, Deswal et al., 2001, Alonso-Martinez et 
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al., 2002, Kell et al., 2002). For example,  in a sub-study to the Studies on Left Ventricular 
Dysfunction (SOLVD), patients with lower plasma levels of TNF-α were found to have a 
better prognosis than those with TNF-α levels > 6.5pg/ml (Torre-Amione et al., 1996). 
Additionally in the Vesnarinone Trial it was found that circulating levels of inflammatory 
cyctokines such as TNF-α and IL-6 and their receptors, such as the soluble TNF-α receptor, 
were independent predictors of mortality in patients with advanced heart failure (Deswal et 
al., 2001).  
 
Section 1.4: Inflammation in the Brain 
 
Cytokine levels are not only increased in the periphery but also in the brain following 
myocardial infarction. There is evidence to show that TNF-α and IL-1β are both increased in 
the brain following a myocardial infarction (Felder et al., 2003, Francis et al., 2004b, Kang et 
al., 2006). TNF-α is significantly increased within the hypothalamus just 30 minutes after a 
myocardial infarction, the same time frame in which increases in the levels of cytokines were 
observed in the plasma and heart tissue (Francis et al., 2004b). Since animals administered 
with a cytokine synthesis inhibitor, pentoxifylline, into the brain ventricles reduced markers 
of neurohumoral activation in heart failure, proinflammatory cytokines in the brain may play 
an important functional role in the progression of heart failure (Kang et al., 2009).  
 
Cytokines are not able to be passively translocated across the blood brain barrier due to their 
size and therefore must either be actively transported or produced locally. The mechanism by 
which cytokines become elevated in the brain following a myocardial infarction is not fully 
understood. There are several potential mechanisms that could contribute. One possibility is 
that circulating cytokines induce cyclooxygenase-2 (COX-2) activity in the cerebral 
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microvasculature (Rivest et al., 2000, Engblom et al., 2002). The principle product of COX-2 
is prostaglandin E2 (PGE2) which is known to increase cytokine production (Ericsson et al., 
1997, Felder et al., 2003). A second possibility is that the activated renin-angiotensin-
aldosterone system in the brain causes an inflammatory response. Angiotensin II and 
aldosterone may act either directly, or via induction of reactive oxygen species, to initiate 
inflammation including the production of cytokines (Felder et al., 2003, Lindley et al., 2004, 
Guggilam et al., 2007). It is also possible that peripheral cytokines act on sites where the 
blood brain barrier is weak or non-existent such as the median eminence, organum 
vasculosum laminae terminalis (OVLT), or the area postrema. Cytokines such as IL-1β can 
penetrate the parenchymal membrane at these sites and then be transported via the 
cerebrospinal fluid to the entire central nervous system (Herkenham et al., 1998).  
 
Although cytokines may be actively transported across the blood brain barrier, local 
production of cytokines can also contribute to the increased levels of cytokines in the brain 
since mRNA levels of pro-inflammatory cytokines are elevated within the hypothalamus as 
early as 30 minutes following myocardial infarction (Francis et al., 2004b). Cytokines 
produced in the brain can arise from several sources including microglia, invading 
inflammatory cells, microvessel endothelial cells, pericytes, choroid plexus and astrocytes 
(Fabry et al., 1993, Sebire et al., 1993, Van Dam et al., 1995, Wong et al., 1995, Mitchell et 
al., 2009). Given the role microglial cells play in immunity and their constant surveillance of 
the environment within the brain, it seems likely that they would play a key role in the 
increased inflammation in the brain. 
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Section 1.5: Microglia 
 
Microglia are the primary immune cells within the brain. At rest these cells have long fine 
processes which are used to constantly survey the environment, with the entire brain being 
surveyed within a few hours (Nimmerjahn et al., 2005). In response to any kind of brain 
insult or injury they undergo morphological and functional changes. Microglial activation 
involves a shortening of the processes and an enlargement of the soma and in this state, 
microglial cells are capable of phagocytosis see figure 1.1 (Kreutzberg, 1996, Liu and Hong, 
2003, Badoer, 2010a, Colton and Wilcock, 2010). Microglia are deemed to be ‘activated’ 
when they undergo these morphological changes, which can be observed with 
immunohistochemical techniques, for example, the use of an antibody which binds to the 
CD11b protein on microglia (Hickey and Kimura, 1988, Aloisi, 2001, Rana et al., 2010, 
Dworak et al., 2012). As well as the morphological changes, activated microglia also secrete 
cytokines and can contribute to the proinflammatory state in a number of conditions, such as 
Alzheimer’s disease, Parkinson’s disease and neuropathic pain (Mrak et al., 1995, Liu, 2006, 
Sawada et al., 2006).  
 
 If microglia contribute to the increase in cytokines then one expects there would be 
activation of microglia in the brain following myocardial infarction. Indeed, this has been 
recently investigated and Rana et al. found that there was an increase in activated microglia in 
the paraventricular nucleus of the hypothalamus (PVN) (Rana et al., 2010). Interestingly the 
activation of microglia was specific for the PVN and was not a general inflammatory 
response as no activation was seen within the cortex or adjacent areas of the hypothalamus 
(Rana et al., 2010). As the PVN is important in cardiovascular regulation, the activation of 
microglia could be important to the cardiovascular changes occurring in heart failure. It 
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remains to be seen if microglia are the initial source of cytokine production in the PVN or 
whether they become activated in response to increasing levels of cytokines. 
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Figure 1.1: Microglia in various states of activation (adapted from (Badoer, 2010a). 
Microglia in their resting state have long fine processes however when activated microglial 
processes are retracted to have a more stubby appearance. 
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Section 1.6: Role of Cytokines in Autonomic Dysfunction Post Myocardial Infarction 
 
As discussed earlier cytokines in the brain are increased following a myocardial infarction 
(Felder et al., 2003). These cytokines may be involved in the autonomic dysfunction, such as 
increased sympathetic nerve activity, seen following a myocardial infarction, since cytokines 
within the hypothalamus have been shown to influence cardiovascular variables. Direct 
injections of TNF-α or IL-1β into the brain can cause an increase in blood pressure and renal 
sympathetic nerve activity (Kimura et al., 1993, Kannan et al., 1996). Central administration 
of IL-1β has also been shown to increase noradrenaline turnover in the liver, spleen and 
pancreas (Vriend et al., 1993, Terao et al., 1994) suggesting an increase in sympathetic nerve 
activity to those tissues. Shi et al. found that microinjections of TNF-α or IL-1β into the PVN 
increased blood pressure and sympathetic outflow to the kidney and enhanced the cardiac 
sympathetic afferent reflex (CSAR) (Shi et al., 2011).  Blocking TNF-α production using 
pentoxifylline administered intraperitonealy attenuates the increase in renal sympathetic 
nerve activity seen in heart failure as well as reducing the TNF-α levels in the PVN 
(Guggilam et al., 2007). Taken together, the findings sugest that it is possible cytokines are 
involved in the autonomic dysfunction seen following a myocardial infarction. 
 
Following a myocardial infarction there is an increase in the neuronal activity in the PVN, 
supraoptic nucleus (SON), subfornical organ and the nucleus of the solitary tract (NTS) 
(Vahid-Ansari and Leenen, 1998). It is interesting to speculate whether the increase in 
neuronal activity is caused by increased levels of cytokines which are also seen following a 
myocardial infarction.  The importance of autonomic dysfunction to the progression of heart 
failure is firmly established with increases in sympathetic nerve activity strongly linked to 
poor prognosis (Cohn et al., 1984, Francis, 1998, Barretto et al., 2009). The PVN can regulate 
many of the neurohumoral systems that are affected in end stage heart failure including 
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sympathetic nerve activity. Thus, the PVN is one of the more extensively studied areas of the 
brain in regard to neurohumoral defects in heart failure.  
 
Section 1.7: The Paraventricular Nucleus (PVN) 
 
The PVN is a bilateral periventricular structure located in the hypothalamus that contains 
separate subpopulations that regulate hormone secretion and autonomic output. The 
magnocellular subpopulation is neurosecretory and plays a vital role in the body’s ability to 
regulate blood volume and fluid retention (Sherman et al., 1986, Coote, 1995, Pyner, 2009). 
The parvocelluar subpopulation projects to more brain regions including those involved in 
autonomic regulation (Coote et al., 1998, Badoer, 2001), such as RVLM, NTS and PAG. (see 
fig 1.2)  
 
There have been many studies showing that the PVN influences sympathetic nerve activity; 
Early electrical stimulation studies showed mixed results; with some studies showing 
increases in sympathetic nerve activity and some showing decreases (Gilbey et al., 1982, 
Kannan et al., 1987, Porter, 1988, Kannan et al., 1989). One disadvantage of electrical 
simulation is that it not only activates the neurons in the area of interest but also passing 
axons. Furthermore, anaesthesia can markedly influence the sympathetic nerve activity 
responses occurring after stimulation of the PVN. Both of these factors have contributed to 
the mixed results. In conscious rats increased sympathetic nerve activity was observed 
following stimulation of the PVN (Kannan et al., 1989).   
 
Chemical stimulation of the PVN overcomes the disadvantage of electrical stimulation as it 
only activates the neurons within the area. Excitatory stimulation with glutamate or 
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bicuculline (to inhibit GABA-mediated inhibition of the PVN) induced an increase in renal 
sympathetic nerve activity and a reduction renal blood flow (Haselton and Vari, 1998). 
Studies in anaesthetised rabbits have shown that microinjections of D,L-Homocysteic acid 
(DLH) into the PVN caused inhibition of sympathetic nerve activity to the kidneys but 
increases sympathetic nerve activity to other organs like the splanchnic, adrenal and cardiac 
nerves (Deering and Coote, 2000) indicating that there may be a differential functional output 
from the PVN. It has been well established that an increased sympathetic nerve activity is a 
characteristic feature of heart failure (Zhang et al., 1997).  
 
Following a myocardial infarction, metabolic activity is increased in both the parvocellular 
and magnocellular regions of the PVN in rats (Patel et al., 1993). In agreement with that work 
Vahid-Ansari and Leenen (1998) demonstrated that Fra-like immunoreactivity, an indicator 
of long-term neuronal activation, was increased in both the magnocellular and parvocellular 
regions of the PVN in rats with a myocardial infarction (Vahid-Ansari and Leenen, 1998). 
The cause of increased neuronal activity within the PVN may be due to a number of different 
factors. One possibility is the increased activation of the renin angiotensin aldosterone system 
since administration of either losartan, an angiotensin type 1 receptor antagonist, or captopril, 
an angiotensin-converting enzyme inhibitor, or spironolactone, a mineralcorticoid receptor 
antagonist, was able to ameliorate the elevated neuronal activity seen in rats with heart failure 
(Zhang et al., 2002b). A second possibility is the role of the excitatory amino acid glutamate 
with studies suggesting the increase in neuronal activity is due to an increase in glutamatergic 
mechanisms within the PVN (Li et al., 2003). A third possibility is a reduction in endogenous 
GABA inhibition within the PVN of heart failure animals (Zhang et al., 2002a). GABA is an 
inhibitory neurotransmitter and a reduction in effectiveness of GABA could allow excitatory 
inputs to play a greater role. Evidence suggests that GABA’s actions involve nitric oxide 
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(Horn et al., 1994, Zhang and Patel, 1998). Therefore an increase in neuronal activity may 
also occur with the reduction of nitric oxide in the PVN in heart failure (Li et al., 2001, 
Zhang et al., 2001). Another possible mechanism for increased neuronal activity is that the 
peripheral cytokines acting on endothelial cells in the blood brain barrier cause the release of 
PGE2 (Ericsson et al., 1997).  PGE2 elicits an increase in neuronal activity as demonstrated 
by the increase in the c-Fos immunoreactivity of PVN neurons, causing an increase in 
sympathetic activation (Zhang et al., 2011). This evidence suggests that excitatory inputs in 
the PVN predominate in ischemia-induced heart failure. At 4 weeks post myocardial 
infarction Fra-like immunoreactivity, an indicator of long-term neuronal activation was 
increased in both the parvocellular and magnocellular portions of the PVN and showed 
significant correlation between the extent of activation and the reduction in left ventricular 
end diastolic pressure (LVDP) (Vahid-Ansari and Leenen, 1998). Few studies have 
investigated the functional changes in specific areas of the brain and their contribution to 
sympathoexcitation post myocardial infarction. It has been shown that rats have increased 
catecholamine turnover in the PVN during coronary artery ligation (Sole et al., 1982). Not 
only is there an increase in neuronal activity, microglia also become activated following a 
myocardial infarction (Rana et al., 2010). Microglia secrete cytokines and can become 
activated by them. It is not known, how early microglia become activated following a 
myocardial infarction. However, elevated levels of cytokines are seen within 30 minutes of a 
myocardial infarction (Francis et al., 2004b).  
 
The PVN also projects to other brain regions that can influence SNA such as the RVLM, 
NTS and PAG. Interestingly, during heart failure some of the PVN neurons that become 
active are neurons that project to the RVLM (Xu et al., 2012). However it is not known 
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whether inflammation and activation of microglia occurs in those regions as well following a 
myocardial infarction. Both of these issues will be explored in this thesis. 
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Figure 1.2: Graphical representation of the neuroanatomical connections between the 
paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), periaquductal gray 
(PAG), area postrema (AP) and the nucleus of the solitary tract (NTS). 
 
 
 
 
 
  
RVLM 
PAG 
PVN 
NTS/AP 
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Section 1.8: The Rostral Ventrolateral Medulla (RVLM) 
 
The RVLM is part of the ventrolateral medulla and located just caudal to the facial nucleus. 
It is involved in the central control of sympathetic outflow and it plays a critical role in the 
tonic and reflex neural control of cardiovascular activity (Campos and McAllen, 1997, 
Schreihofer and Guyenet, 2002, Dampney et al., 2007, Campos et al., 2008). It contains 
presympathetic neurons that directly project to the IML in the spinal cord (Schreihofer and 
Guyenet, 2002, Dampney et al., 2003, Campos et al., 2008). The basal activity of 
presympathetic neurons in the RVLM is an important mechanism responsible for the 
generation of resting blood pressure and sympathetic outflow (Schreihofer and Guyenet, 
2002, Dampney et al., 2003, Campos et al., 2008).  Therefore, drugs that influence the 
activity of these neurons can influence SNA. 
 
The RVLM is able to influence both sympathetic nerve activity and blood pressure. It has 
been shown in anaesthetized animals, that bilateral inactivation or ablation of neurons in the 
RVLM leads to a profound fall in arterial pressure and sympathetic nerve activity (Feldberg 
and Guertzenstein, 1972, Dampney and Moon, 1980, Willette et al., 1983). Both 
neuroinhibitory and neuroexcitatory compounds are able to influence the sympathetic output 
from the RVLM. Microinjection of the neuroinhibitory compound, glycine, into the RVLM 
showed a large decrease in arterial pressure as well as sympathetic nerve activity (Sakima et 
al., 2000) whilst microinjections of the excitatory amino acid, glutamate, increases 
sympathetic nerve activity (Dampney and McAllen, 1988, Mueller, 2007).  
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Other potential neurotransmitters can also influence the function of the RVLM. Activation of 
ATP receptors in the RVLM causes marked increases in blood pressure, heart rate and renal 
sympathetic nerve activity (Sun et al., 1992, Horiuchi et al., 1999, Ralevic et al., 1999, Spyer 
and Thomas, 2000). Recently Marina et al showed that ATP-mediated purinergic signalling 
in the RVLM contributes to sympathoexcitation and worsens left ventricular function 
(Marina et al., 2013). Intracerebroventricular Ang ІІ infusions also cause an increase in 
sympathetic nerve activity, whilst blocking the actions of Ang ІІ using losartan will cause a 
decrease in sympathetic nerve activity (Gao et al., 2004, 2005). These effects are enhanced 
during heart failure and this is believed to be due to an increase in the levels of angiotensin ІІ 
type 1 (AT1) receptors within the RVLM in heart failure animals (Zucker et al., 2004b, Gao 
et al., 2005).  
 
Section 1.9: The Periaqueductal Gray (PAG) 
 
The PAG is the gray matter surrounding the cerebral aqueduct in the midbrain. It is organised 
into four basic longitudinal columns these are: dorsomedial, dorsolateral, lateral and 
ventrolateral columns. The PAG is thought to contribute to a wide range of behavioural and 
physiological reactions in animals including pain modulation, defensive reactions, 
cardiovascular regulation, vocalization and reproductive behaviour (Bandler and Shipley, 
1994, Behbehani, 1995). The defensive reactions seen with stimulation of the PAG are 
dependent on the columns stimulated, the lateral column is involved in active defensive 
reactions and the ventrolateral column is involved with passive defensive reactions (Carrive 
and Morgan, 2004). The columns of the PAG have similar connections but they have 
different effects on blood pressure and heart rate; the lateral column eliciting an increase in 
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blood pressure and heart rate, the ventrolateral column, on the other hand reduces blood 
pressure and heart rate (Carrive and Morgan, 2004, Green et al., 2005).   
 
The PAG is an important integrating centre in the brain. It is located at the crossing of the 
ascending pain sensory system and the descending limbic motor system (Carrive and 
Morgan, 2004) which has led to the PAG being thought of as an area which can influence 
perception of pain. Early studies in rats showed that the PAG can induce analgesia such that 
PAG stimulation provided sufficient analgesia to perform abdominal surgery (Reynolds, 
1969). Many subsequent studies confirmed the PAG as an analgesia center and led to the 
development of PAG stimulation as a treatment for chronic pain in humans.   The PAG is one 
of the few brain areas that has been implanted with chronic electrodes and stimulated in 
awake humans (Green et al., 2005, Carter et al., 2011). 
 
Neuroanatomical studies have shown that the PAG projects to other cardiovascular areas 
within the brain such as the RVLM (Carrive and Morgan, 2004). These studies highlight the 
anatomical connections that contribute to the cardiovascular changes. In humans blood 
pressure and heart rate can be influenced by electrical stimulation of the PAG (Green et al., 
2005). PAG neurons can influence cardiac output though projections to the cardiac vagal 
preganlionic neurons in the nucleus ambiguous (NA), dorsal motor nucleus of the vagus 
nerve (DMNV) and NTS (Farkas et al., 1997). It has also been shown that many of the 
descending connections from the hypothalamus pass through, and are influenced by, the 
PAG. For example the hypotensive response elicited by lateral hypothalamus stimulation can 
be attenuated by a lidocaine injection into the PAG (Pajolla et al., 2005).  
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Section 1.10: The Area Postrema (AP) 
 
The AP is a medullary structure located at the caudal end of the fourth ventricle. It is one of 
the circumventricular organs, and has a fenestrated capillary endothelium allowing 
communication between the peripheral circulation and the central nervous system. The 
circumventricular organs play a critical role as transducers of information between the blood, 
neurons and the cerebral spinal fluid (CSF) (Cottrell and Ferguson, 2004).  Precise regulation 
of cardiovascular function requires the central integration of neural and humoral signals from 
the periphery.  
 
The AP is a well-known pressor area with both chemical and electrical stimulation able to 
increase blood pressure in dogs and rats (Barnes et al., 1984, Skoog and Mangiapane, 1988). 
Receptors for hormones involved in cardiovascular regulation such as Angiotensin ІІ (Ang ІІ) 
are located in the AP are in fact required for the chronic development of Ang ІІ-dependant 
hypertension (Mendelsohn et al., 1984, Song et al., 1992, Zini et al., 1997). Interestingly 
although the AP causes a dose dependant increase in blood pressure it does so without 
producing considerable changes to heart rate (Fink et al., 1987, Cox and Bishop, 1991). 
Additionally, AP lesion studies have shown the AP to be critical in the baroreflex responses 
to acute blood pressure changes (Undesser et al., 1985, Peuler et al., 1990, Bishop and 
Sanderford, 2000).  
 
The AP projects to brain regions known to be involved in cardiovascular regulation including 
the RVLM, parabrachial nucleus and NTS. Chemical stimulation of the AP can modulate the 
neuronal activity in the NTS, for example vasopressin acts on the AP to increase the 
excitatory response of the NTS, whilst Ang ІІ stimulation of the AP can cause an inhibitory 
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response in the NTS (Cai et al., 1994). Perhaps, given the close proximity of the AP and 
NTS, it is not surprising to find they have a strong connection.  
 
Section 1.11: The Nucleus of the Solitary Tract (NTS) 
 
The NTS is a series of small nuclei clustered together to form vertical columns of grey matter 
though the dorsomedial region of the medulla oblongata. It plays a key role in the regulation 
of blood pressure and heart rate. The NTS is the site for primary termination of many sensory 
inputs which include the arterial baroreceptor afferents (Spyer, 1981, Reis et al., 1984) and 
the peripheral chemoreceptors (Mifflin, 1992, Sapru, 1996). The NTS is also the region in 
which ascending fibers from the cardiac sympathetic afferents terminate (Kuo et al., 1984). 
Given that the NTS receives inputs from the peripheral chemoreceptors and from cardiac 
sympathetic afferents it’s not surprising that the interaction between the cardiac sympathetic 
afferent reflex (CSAR) and chemoreflexes happens within the NTS (Wang et al., 2008).  
 
In rabbits with heart failure it has been shown that the AT1 receptors in the NTS are 
upregulated (Zucker et al., 2004a). Similar to the findings in the RVLM, losartan injections in 
the NTS reduce blood pressure, heart rate and renal SNA in heart failure animals but do not 
influence cardiovascular function in sham animals (Mancia et al., 1992, Wang et al., 2007). 
Therefore, increased Ang ІІ and upregulated AT1 receptors in the NTS may be contributing 
to the increased sympathoexcitation seen in heart failure.  
 
In heart failure there is also an increase in superoxide production within the NTS (Wang et 
al., 2008). Injections of the superoxide dismutase mimetic, tempol, in the NTS had a 
beneficial effect on sympathetic activity and baroreflex sensitivity in animals with heart 
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failure (Wang et al., 2008). Since the NTS receives information from many different sources 
including from the AP, PVN and PAG; the NTS is able to integrate information and play a 
key role in cardiovascular regulation.   
 
Section 1.12: Summary 
 
Heart failure is a major cardiovascular disease state and an increasing burden on our society 
and health care budget. Following a myocardial infarction there is an increase in 
inflammatory cytokine levels in the brain which occurs within 30 minutes. The increase in 
cytokines may result from either peripherally produced cytokines being transported across the 
blood brain barrier, and/or local production, as mRNA levels of pro-inflammatory cytokines 
are elevated following a myocardial infarction. This local production could involve the 
immune cells of the brain. Microglia are the primary immune cells in the brain and when 
activated they secrete cytokines thereby potentially contributing to the local elevation in pro-
inflammatory cytokines. A recent study has shown that 2-5 weeks following a myocardial 
infarction, microglia become activated within the PVN (Rana et al., 2010). However it is not 
known how soon after a myocardial infarction, microglia become activated and whether they 
are responsible for the initial increase in cytokines or become activated as a result of 
increased cytokines. Furthermore, it is not known whether activation of microglia is limited 
to the PVN, or if other brain regions involved in cardiovascular regulation are also affected. 
While we know that following a myocardial infarction neuronal activity increases in several 
brain regions, it would be of interest to see if inhibiting the activation of microglia influences 
local neuronal function and cardiac function.  
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Section 1.13: Aims 
 
Therefore the aim of this work was to  
(i) Investigate the time course for the activation of microglia following a myocardial 
infarction 
(ii) Determine if microglia become activated within other key brain regions following 
a myocardial infarction 
(iii) Determine whether neuronal activation following a myocardial infarction occurs 
in regions where microglia become activated and  
(iv) Investigate if blocking microglial activation influences neuronal activation and 
cardiac function. 
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Chapter 2: Methods 
Section 2.1:  Animal housing 
 
Male SPF (Specific Pathogen Free) Sprague-Dawley rats obtained from the Animal Resource 
Centre (ARC, Western Australia, Australia) were used in these studies. The animals were 
housed in a temperature-controlled room on a 12:12 hour light/dark cycle, in the Animal 
Facility (RMIT University, Victoria, Australia), where rat chow and tap water were available 
ad libitum. The animals were held for a minimum period of one week prior to undergoing any 
experimental procedure.     
 
All experimental protocols used in this study were performed in accordance with the 
Prevention of Cruelty to Animals Act 1986 and conform to the guidelines set out by the 
National Health and Medical Research Council of Australia  and were approved by the RMIT 
University Animal Ethics and St Vincent’s Hospital Animal Ethics Committees. Every 
attempt was made to minimize animal suffering, discomfort and reduce the number of 
animals needed to obtain reliable results. Animals were also handled on a daily basis prior to 
the experimental day to minimize stress.  
 
Section 2.2:  Surgical preparation of animals 
 
All surgical procedures were performed under general anaesthesia.  At the completion of 
surgery 0.1ml buprenorphine (Temgesic® 1.5mg/ml, Reckitt and Coleman Pharmaceuticals, 
NSW, Australia) was routinely administered subcutaneously for analgesia. All surgical 
procedures were performed under aseptic conditions with sterilized instruments. 
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Section 2.3: Myocardial infarction 
 
The animals were intially anesthetised with 10mg/kg Alfaxalone (Alfaxan®, Jurox NSW, 
Australia.) intravenously (i.v). Each animal was then intubated using a 16 gauge catheter 
plastic tube. For intubation the animal was placed on its back with head extended and a light 
source directed over the throat region to facilitate visualisation of the vocal cords, enabling 
placement of the tube into the trachea. The animal was then connected to a ventilator via the 
protruding end of the tube and received 3% isoflurane/97% oxygen with a tidal volume of 
2ml /100g body weight, at a rate of 60 breaths/min, to maintain anaesthesia during the course 
of surgery. Body temperature was maintained throughout the experiment by placing the 
animal on a heated pad. The chest was shaved and swabbed with 70% ethanol to disinfect the 
area. An incision of approximately 5cm was made into the skin 1-2cm to the left of the 
sternum and blunt dissection of the underlying muscle layers was used to expose the fourth 
intercostal space. A thoracotomy was performed through the fourth intercostal space and the 
ribs held open using retractors to enable access to the heart. The pericardial sac surrounding 
the heart was opened and a 6-0 prolene suture was used to ligate the left anterior descending 
coronary artery (LAD) immediately below its point of origin. A sham operation involved the 
same procedure except that the suture was passed through the myocardium beneath the LAD 
without ligation. At this point, isoflurane was reduced to 1% and respiratory rate was 
increased to 70 breaths per minute to facilitate clearance of the gaseous anaesthetic. Atropine 
was administered (0.6mg/kg, subcutaneous administration (s.c), Atropine, Sigma, St Louis, 
USA) to reduce bradycardia and to reduce the likelihood of cardiac arrest. Lignocaine 
(12mg/kg, intramuscular administration (i.m.), Lidocaine, Sigma, St Louis, USA) was also 
administered to reduce the likelihood of cardiac arrhythmia. The retractors were removed and 
the chest cavity was flushed with warm 0.9% saline to dissolve any accumulated blood. The 
ribs were closed with 3-0 silk sutures and positive pressure was applied to the lungs via the 
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ventilator to reduce the risk of pneumothorax. The muscle and skin layers were closed 
separately using 3-0 silk sutures. Isoflurane was then turned off and the animals remained 
connected to the ventilator until robust spontaneous respiration was re-established. The area 
around the skin sutures was swabbed with saline, followed by 70% ethanol to disinfect the 
area. The wound was dressed with Opsite® spray (Smith and Nephew Limited, 
Hertfordshire, England) to reduce the risk of infection. 
 
Section 2.4: Echocardiography Measurements 
 
To perform an echocardiograph the animal was placed either (i) in an induction chamber and 
a gaseous mixture of 95% oxygen and 5% isoflurane was used to initially anaesthetise the 
animal. Within 5 minutes, the animal was sufficiently anaesthetised (indicated by a lack of 
both pedal and corneal reflexes, muscle relaxation and a drop in respiratory rate) to be 
removed from the induction chamber. The animal was then placed supine on a heating pad to 
maintain body temperature with a nose cone placed over the mouth and nose for continuous 
anaesthesia. The anaesthesia was maintained at 3% isoflurane/97% oxygen; or (ii) 
anaesthesia was provided using ketamine and xylazine (80mg/kg and 10mg/kg respectively 
i.p). The chest was shaved and a conductive gel was applied to the shaved chest. Images of 
the heart were obtained using a Vivid 7 echocardiography machine with a 10-MHz phased 
array probe (GE Vingmed, Horten, Norway). Images were taken from a 2-dimensional 
parasternal short axis view of the left ventricle at the mid-papillary muscle level from which 
one-dimensional M-mode images were produced (see fig M1). These M-mode images were 
then used to determine the ejection fraction, percent fractional shortening, stroke volume, 
intra-ventricular septal thickness (systolic and diastolic), left ventricular internal diameter 
(systolic and diastolic), left ventricular posterior wall dimensions (systolic and diastolic), 
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end-diastolic volume and end systolic volume. All parameters were assessed using the 
average of 3 consecutive cycles. 
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Figure 2.1: Echocardiogram showing a 2-dimesion parasternal view of the left ventricle and a 
one-dimensional M-mode image with the left ventricle wall in systole and diastole, from 
which the ejection fraction (EF), percent fractional shortening (%FS), stroke volume (SV), 
intra-ventricular septal thickness in systole (IVSs), intra-ventricular septal thickness in 
diastole (IVSd), left ventricular internal diameter in systole (LVIDs), left ventricular internal 
diameter in diastole (LVIDd), left ventricular posterior wall dimensions in systole (LVPWs), 
left ventricular posterior wall dimensions in diastole (LVPWd), end-diastolic volume (EDV) 
and end systolic volume (ESV) were calculated. 
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Section 2.5: Implantation of cannula into lateral brain ventricle 
 
Anaesthesia was induced and maintained in rats with inhalational isoflurane. The animal was 
placed in an induction chamber and a gaseous mixture of 95% oxygen and 5% isoflurane was 
used to initially anaesthetise the animal. Within 5 minutes, the animal was sufficiently 
anaesthetised (indicated by a lack of both pedal and corneal reflexes, muscle relaxation and a 
drop in respiratory rate) to be removed from the induction chamber. The animal was then 
placed prone in a Kopf stereotaxic frame, such that both bregma and lambda were positioned 
on the same horizontal plane, with a nose cone to allow for continuous gas anaesthetic. The 
animals received 3% isoflurane/97% oxygen in a tidal volume of 2ml/100g body weight to 
maintain anaesthesia during the course of surgery. A midline incision was made to expose the 
skull and any overlying membrane tissue was scraped away. A burr hole, approximately 3 to 
4mm in diameter, was drilled into the  bone on the left hand side of the skull with its centre 
approximately 1.6mm lateral of the mid-sagittal suture and 0.8mm caudal to bregma. A 
cannula (Alzet® Brain infusion kit, Durect Corporation, Cupertino. USA) connected to an 
Alzet minipump see figure 2.2 (Alzet® Mini-Osmotic pump, Durect Corporation, Cupertino. 
USA) containing a solution of either 0.9% saline or 127µg/ml minocycline in 0.9% saline 
was then placed at 1.6mm lateral of the mid-sagittal suture and 0.8mm caudal to bregma  and 
a depth of 5mm from the skull surface to allow a direct infusion into the lateral ventricle. The 
cannula was then fixed to the surface of the skull with glue (3M VetbondTM Tissue adhesive, 
3M Animal care products, Minnesota, USA). A subcutaneous pocket was made via blunt 
dissection to the level of the shoulder blades of the animal to allow the minipump to sit 
between the shoulder blades. Using 5.0 silk the head wound was stitched closed with a 
running subcuticular suture to reduce the likelihood of animals removing their sutures. The 
area around the skin sutures was swabbed with saline, followed by 70% ethanol to disinfect 
the area. The wound was dressed with Opsite® spray to reduce the risk of infection.
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Figure 2.2: Alzet brain infusion cannula with pump connected adapted from Alzet® website 
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Section 2.6: Post – Operative care of animals 
The recovery of animals following all surgical procedures utilised in this study was closely 
monitored. The appearance of the animal was observed, with particular attention to 
demeanour, alertness, signs of pain (piloerection or vocalisation) and grooming behaviour, 
posture, movement around the cage, drinking, eating, activity and bowel movements (See 
appendix 1).   
 
Section 2.7: Tissue collection 
At the completion of all experiments, rats were killed with an overdose of pentobarbitone 
150mg/kg, i.v (Lethabarb, Virbac Animal Health Pty Ltd., NSW, Australia). The heart and 
lungs were removed and weighed. To determine the infarct sizes, the hearts were placed in 
4% paraformaldehyde solution for at least 1 day, then placed into a solution of phosphate 
buffered saline containing 30% sucrose until sectioned. They were then mounted onto a 
chuck using cryomatrix (OCT media-Optimal Cutting Temperature, Sakura Finetek, USA.) 
and cut, using a cryostat (Leica, CM1900), into 20µm-thick sections. One in 20 sections were 
collected and stained using a standard hematoxylin and eosin stain. Infarct sizes were 
determined by expressing the damaged epicardial and luminal surfaces as a percentage of 
total circumference. Only animals with a transmural infarction were used in this study.  
 
The brains were carefully removed and fixed in 4% paraformaldehyde solution for 4 hours, 
then placed into a solution of phosphate buffered saline containing 30% sucrose until 
sectioned. For each brain two blocks of tissue were prepared. The brainstem was separated 
from the cerebral hemispheres.  The blocks were mounted onto a chuck using cryomatrix 
35 
 
(OCT media-Optimal Cutting Temperature, Sakura Finetek, USA.) and the chuck balanced to 
yield coronal sections corresponding to the Rat Atlas by Paxinos and Watson(Paxinos and 
Watson, 1986). In this study, serial coronal sections were taken for immunohistochemical 
analysis.  
 
Section 2.8: Immunohistochemical Processing for CD11b (clone OX-42) 
 
To identify activated microglia, immunohistochemistry to detect CD11b (clone OX-42) was 
performed. The sections were incubated and processed using standard immunohistochemical 
procedures. The sections were mounted on slides coated with gelatine and left to dry. 
Sections then underwent washes in Phosphate Buffered Saline (PBS) prior to incubation with 
10% normal horse serum (NHS) in PBS for one hour at room temperature. This was followed 
by a 72 hour incubation with a primary antibody raised in mouse against CD11b (clone OX-
42) (Chemicon, Temecula, USA) 1:100 dilution in PBS containing 2% NHS (JRH 
Biosciences, Australia) and 0.3% Triton X-100 (Sigma Aldrich, Australia) at 4°C. After 
washes in PBS, the sections were incubated for two hours with biotinylated anti-mouse 
secondary antibody (diluted to 1:600 in 0.1M PBS, (Vector Laboratories, Burlingame, USA) 
that was raised in rabbit. Following washes in PBS, the sections were incubated for one hour 
using Extravidin (Sigma Aldrich, St Louis, USA) diluted to 1:400 in 0.1M PBS. 
Subsequently, the sections were then washed in Tris buffer (0.05M, pH 7.6) and incubated for 
ten minutes in 0.05% 3,3’-diaminobenzidine hydrochloride (DAB) (Sigma Aldrich, St Louis, 
USA) in 0.05M Tris Buffer. The reaction was initiated by the addition of 5µl of 30% 
hydrogen peroxide (H2O2) (Biotech Pharm, NSW, Australia) and terminated by washes with 
fresh 0.05 M Tris Buffer. The slides were dehydrated by dipping them in an alcohol series 
(50%, 70%, 100% ethanol). The slides were then dipped in Xylene (Analar, Merck Pty Ltd, 
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NSW, Australia) before being cover-slipped using DePex mounting medium (BDH, Poole, 
UK). 
 
Section 2.9: Immunohistochemical Processing for FRA proteins 
 
To identify increased neuronal activation, immunohistochemistry to detect Fos related 
antigens (FRA) was performed. The procedure used was similar to that described above 
however the primary antibody used was raised in rabbits against FRA (FRA raised in rabbit 
antibody, Santa Cruz Biotechnology, Oregon, USA) 1:400 dilution in PBS containg 2% NHS 
and 0.3% Triton X-100 then incubated for 24hrs at room temperature. The secondary 
antibody used was biotinylated goat anti rabbit (diluted 1:600 in 0.1M PBS, Invitrogen, 
Victoria, Australia). The incubation lasted for 2 hrs at room temperature. In all other respects 
the sections were processed as described above.   
 
Section 2.10: Histological analysis 
 
Immunohistochemistry to detect the protein CD11b (clone OX-42) was used to observe the 
microglia present.  Non-activated microglia were identified by their small soma from which 
there emanated extensive, highly branched, long, thin processes. Activated microglia were 
defined by three main criteria; (1) stronger immunohistochemical staining for the marker 
CD11b (clone OX-42), (2) the presence of a clearly enlarged soma, and (3) marked changes 
in the appearance of the processes which were now reduced in number, but considerably 
thicker and shorter giving a stubby appearance. Only microglia with these changes were 
defined as activated. In each brain region analysed the number of microglia present was 
counted in squares, each 0.2 x 0.2 mm in size at 400 times magnification as shown 
diagrammatically in figures 2.3-2.5.  Within these squares, the number of activated microglia 
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was counted and expressed as a percentage of the total number of microglia (activated + non-
activated). For each brain region analysed, an adjacent area was counted to serve as a control 
using the same sized squares (See Figures 2.3-2.5). The total number of microglia and the 
percent of activated microglia were then averaged for each region analysed. 
 
Immunohistochemistry for the FRA proteins was used to detect increased activity of neurons. 
For this study neurons were only counted if there was clear nuclear FRA staining. The counts 
were performed in a similar manner to the counting of microglia. FRA-positive cell nuclei in 
each brain region were counted in squares, each 0.2 x 0.2 mm in size, at 400 times 
magnification as shown diagrammatically in figures 2.3-2.5.  The total numbers of FRA-
positive cell nuclei for each square was recorded. The number of cells counted was then 
averaged for each brain region. Each brain region also had an adjacent area counted to serve 
as a control (See Figures 2.3-2.5). Analysis was performed by a single observer blinded to the 
treatment. 
 
Section 2.11: Statistical analysis 
 
The data was compared using a one-way ANOVA to determine overall significance between 
groups. If statistical differences were obtained, then subsequent comparisons between 
individual groups and the sham group were made using Dunnet’s test 
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Figure 2.3: Different rostral-caudal levels of the hypothalamus used in counting FRA-
positive cell nuclei and activated microglia in paraventricular nucleus (PVN) sections (a) 
rostral PVN -1.4mm from bregma (b) mid PVN -1.8mm from bregma (c) caudal PVN -
2.0mm from bregma. Shaded boxes represent areas counted inside the PVN and open boxes 
represent the areas counted adjacent to the PVN. Optic tract (OT) 
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Figure 2.4: Different rostral-caudal levels of the periaqueductal grey (PAG) used in counting 
FRA-positive cell nuclei and activated microglia in PAG sections (a) -5.6mm from bregma  
(b)-6.3 mm from bregma (c)-6.9 from bregma (d) -7.5mm bregma. Shaded boxes represent 
areas counted inside the different sub nuclei of the PAG; the dorsomedial PAG (DM), the 
lateral PAG (L), the dorsolateral PAG (DL) and the ventrolateral PAG (VL). Open boxes 
represent the areas counted adjacent to the PAG. 
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Figure 2.5: Different rostral-caudal levels of the medulla used in counting FRA-positive cell 
nuclei and activated microglia in medulla sections (a) Rostal Ventrolateral Medulla (RVLM) 
-12.2mm from bregma at the approximate level used for all three sections counted (b) rostral 
Nucleus Tractus Solitarii (NTS) -13.7mm caudal from bregma (c) mid NTS and Area 
postrema (AP) -14.2mm caudal from bregma (d) caudal NTS -14.5mm caudal from bregma. 
Shaded boxes represent areas counted inside the RVLM, NTS and AP. The open boxes 
represent the areas counted adjacent to the RVLM, NTS and AP. Nucleus Ambiguus (NA), 
Spinal Trigeminal Nucleus (STN), Inferior Olivary Nucleus (ION) and Pyramidal Tracts 
(Pyr). 
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Chapter 3: Time course for activation of microglia in the PVN following 
myocardial infarction  
 
Section 3.1: Introduction 
 
The most common cause of heart failure is myocardial infarction.  The development of heart 
failure following myocardial infarction is a common problem in the elderly and it is the 
fastest growing cardiovascular disorder. Heart failure has a poor prognosis with mortality 
rates of 50% within 5 years of diagnosis (Kaye et al., 1995).  Characteristics of heart failure 
include an elevation in sympathetic nerve activity to the heart and kidneys and there is also 
marked attenuation of cardiovascular reflexes particularly the cardiopulmonary vasomotor-
volume reflex (ie the reflex reduction in renal sympathetic nerve activity which normally 
occurs in response to increases in blood volume) and the arterial baroreceptor-vasomotor 
reflex (Packer, 1988, Mann, 1999).  The restraining influences on sympathetic nerve activity 
of these reflexes are therefore diminished in heart failure and may contribute to the elevation 
in sympathetic drive seen in this condition. The primary cause, however, of sympathetic over 
activity in heart failure is still unknown. Recent research has focussed on the hypothalamic 
paraventricular nucleus (PVN), a key neurohumoral integrative nucleus in the brain (Felder et 
al., 2003, Francis et al., 2004a, Guggilam et al., 2007, Zheng et al., 2009, Badoer, 2010b).  
 
The PVN has direct and indirect neuroanatomical connections to sympathetic preganglionic 
motor neurons located in the intermediolateral cell column of the thoracolumbar spinal cord 
(Swanson and Sawchenko, 1983, Shafton et al., 1998), and pharmacological manipulation of 
the neuronal activity within the PVN can markedly alter sympathetic nerve activity (Patel, 
2000, Li and Patel, 2003). Furthermore, the PVN is essential to the normal function of the 
cardiopulmonary vasomotor-volume reflex (Ng et al., 2004).  
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Following a myocardial infarction there is increased neuronal activity within the PVN which 
contributes to the abnormally elevated sympathetic nerve activity (Patel et al., 1993, Lindley 
et al., 2004), and there is an elevation of pro-inflammatory cytokines (Felder et al., 2003, 
Francis et al., 2004a, Francis et al., 2004b). Central administration of TNF-alpha elevates 
neuronal activity in the PVN and increases sympathetic nerve activity (Zhang et al., 2003) 
suggesting central inflammatory mediators can induce sympatho-excitatory responses. Thus, 
the increase in pro-inflammatory cytokines in the PVN may contribute to the elevation in 
sympathetic nerve activity observed following myocardial infarction. This view is supported 
by findings that show that blockade of the actions of TNF-alpha into the PVN, can attenuate 
the neurohumoral activation seen in heart failure (Kang et al., 2008).  
 
The mechanisms responsible for elevating cytokines in the hypothalamus are unclear, 
however, the brain’s immune cells, microglia, which are known to secrete pro-inflammatory 
cytokines, may contribute (Streit et al., 1988, Streit and Kreutzberg, 1988, Nakajima and 
Kohsaka, 2001, Stence et al., 2001, Nimmerjahn et al., 2005, Badoer, 2010a). Microglia are 
glial cells in the brain that play key immune roles when the brain undergoes an insult or 
injury. Microglia are constantly sensing their environment in their ‘resting’ state 
(Nimmerjahn et al., 2005), but, in response to stressful stimuli, brain injury or infection, 
microglia become activated and undergo dramatic morphological changes (Streit et al., 1988, 
Streit and Kreutzberg, 1988, Nakajima and Kohsaka, 2001, Stence et al., 2001). In a recent 
study, we found that microglia were activated in the PVN following a myocardial infarction 
in the rat and that this effect was specific to that nucleus since adjacent areas of the 
hypothalamus did not show such changes (Rana et al., 2010). Since activated microglia 
secrete cytokines they could contribute to the local elevation of pro-inflammatory cytokines 
in the PVN following myocardial infarction.  The aim of the present study was to investigate 
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in detail the timeframe of the activation of microglia to assess two key issues; (1) how soon 
after myocardial infarction is the activation of microglia observed, and (2) whether the 
activation of microglia is sustained. Thus, we examined the activation of microglia in the 
PVN 24hrs -16 weeks following a myocardial infarction in rats. Additionally, we determined 
whether the proportion of activated microglia correlated with infarct size and cardiac 
function. Immunohistochemistry for the protein marker CD11b (clone OX-42) and 
morphological changes of microglia were used to determine activation of microglia.  
 
Section 3.2: Materials and Methods 
 
Experimental Protocols 
Under general anesthesia (3% isoflurane in oxygen), a myocardial infarction was induced by 
ligation of the left anterior descending coronary artery (N = 25 survived) as previously 
described (Kompa et al., 2008).  Adequate surgical anaesthesia was determined by the 
absence of the pedal and corneal reflexes.  Sham animals underwent the same procedure 
except the coronary artery was not tied (N = 17).  In an additional group of rats (N = 12) no 
surgery was performed.  All animals were monitored daily and allowed free access to food 
and water.  At weeks one (N = 3), four (N = 3), eight (N = 4), twelve (N = 3) and sixteen (N 
= 5) after the myocardial infarction or the sham procedure, the rats were anaesthetized with 
ketamine and xylazine (80 mg/kg and 10 mg/kg respectively i.p.) and echocardiography was 
performed using a Vivid 7 echocardiography machine with a 10-MHz phased array probe 
(GE Vingmed, Horten, Norway).  No supplemental doses of anaesthetic were required since 
adequate depth of anaesthesia for at least 90 minutes was achieved which was sufficient to 
obtain echocardiographic images (this procedure took 5 minutes by the experienced 
sonographer) and to perform cardiac catheterization.  Echocardiographic images from a 2 
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dimensional parasternal short axis view of the left ventricle at the mid-papillary muscle level 
and one dimensional m-mode images were used for the determination of percentage 
fractional shortening (Phrommintikul et al., 2008, Rana et al., 2010).  All parameters were 
assessed using an average of 3 consecutive cycles, and calculations were made in accordance 
with the American Society of Echocardiography guidelines (Schiller et al., 1989). All data 
were acquired and analysed offline by a single blinded observer using EchoPAC (GE 
Vingmed, Horten, Norway) as previously described (Rana et al., 2010).  Immediately after 
the echocardiography procedure, a Millar catheter was introduced into the left ventricle via 
the right carotid artery to measure left ventricular end diastolic pressure and obtain dP/dtmax 
(a measure of left ventricular contractility). Measurements were made with steady state 
baseline pressure-volume loops recorded for 5 minutes after a stabilization period of 10 
minutes (Pacher et al., 2008). For technical reasons the hemodynamic and echocardiography 
measurements could not be obtained from one sham rat.  
 
On completion of the hemodynamic measurements, the animals, under anaesthesia, were 
decapitated. In animals in which the brains were taken 24hrs after the myocardial infarction 
(N = 4) or sham ((N = 4) procedures, the echocardiography and hemodynamic measurements 
were not performed.   
 
 
Tissue collection  
The brains were removed and immediately immersed in freshly prepared, ice cold 4% 
paraformaldehyde in phosphate buffered saline (PBS) (0.1M, pH 7.2) and stored for 4 hours 
at 4oC. The brains were then transferred to a solution containing 30% sucrose in PBS and left 
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for approximately 48 hours at 4oC.  
 
 
Immunohistochemistry 
Microglia were detected immunohistochemically by the presence of the marker protein 
CD11b. Serial coronal sections (40 µm thick) of the brain were cut using a cryostat (Leica, 
CM1900). One in five sections was collected, placed onto gelatin coated slides, dried for 2 
hours at room temperature and then processed immunohistochemically.  Standard 
immunohistochemical procedures were performed as described in detail in chapter 2 
 
 
Morphological analysis and quantification 
Heart 
In all animals the atria and right ventricle of the heart were removed.  The left ventricle 
(including the interventricular septum) was cross-sectioned into 2 halves at the mid-papillary 
level, and fixed in 10% neutral buffer formalin for 24 hours, paraffin embedded and sliced 
into 4 µm-thick sections placed on slides and dried at 37oC overnight before staining with 
hematoxylin and eosin.  Infarct sizes were determined by expressing the damaged epicardial 
and luminal surfaces as a percentage of total circumference. Only animals with a transmural 
infarction were used in this study.  
 
 
Microglia 
Morphological analysis and quantification of microglia was performed with a light 
microscope using 400 times magnification. Two rostral-caudal levels of the PVN 
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(approximately 1.4 – 2.0 mm caudal to bregma) were examined in this study. At each level, 
the PVN was examined unilaterally in one section. The number of microglia were counted in 
two squares, each 0.2 x 0.2 mm in size as shown diagrammatically in figure 3.1.  Within 
these same regions, the number of activated microglia were also counted and expressed as a 
percentage of the total number of microglia (activated + non-activated). Analysis was 
performed by a single observer blinded to the treatment. 
 
Non-activated microglia were identified by their small soma from which there emanated 
extensive, highly branched, long, thin processes. Activated microglia were defined by three 
main criteria; (1) stronger immunohistochemical staining for the marker CD11b (clone OX-
42), (2) the presence of a clearly enlarged soma, and (3) marked changes in the appearance of 
the processes which were now reduced in number, but considerably thicker and shorter giving 
a stubby appearance (figure 3.2).   
 
 
Statistical analysis  
The data from sham animals from the different time points were similar and were combined 
for the purposes of analysis. Non-operated rats were also grouped together. The data were 
compared using one-way ANOVA to determine overall significant differences between 
groups. If a statistical difference was obtained, subsequent comparisons between individual 
groups and the sham group were made using Dunnet’s test.  
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Figure 3.1: Schematic digrams of transverse sections of the rat brain at two levels of the 
hypothalamic paraventricular nucleus (PVN). Microglia were counted in the shaded squares 
indicated at each level.  The approximate distance in mm from bregma is shown. 
Abbreviations: Fx, fornix; 3V, third ventricle.  
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Figure 3.2: Photomicrographs of non-activated and activated microglia taken from the 
hypothalamus of a rat 12 weeks following a myocardial infarction. The photo of activated 
microglia was taken from within the paraventriular nucleus and the photomicrograph of the 
non-activated microglia was taken from the area adjacent to the paraventricular nucleus in the 
same rat. Magnification was 200X for both photomicrographs.  
  
Non-activated Activated 
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Section 3.3: Results 
 
Activation of microglia in the hypothalamic PVN  
The average number of microglia counted in the PVN were not significantly different 
between the different groups of rats used in the present study. In sham rats there were few 
microglia with an activated morphology in the PVN, and this was not different from that 
observed in the non-operated group of rats (figure 3.3).  Twenty-four hours and 1 week 
following myocardial infarction there was no significant increase in the proportion of 
activated microglia compared to the sham group (figure 3.3).  In contrast, at 4, 8, 12 and 16 
weeks following myocardial infarction, activated microglia were present in the PVN (figure 
3.3).  The proportion of activated microglia in the infarcted animals four weeks or more after 
myocardial infarction averaged approximately 40-50% (figure 3.3).  This increase was 
significantly greater compared to the sham group (P<0.001, One-way ANOVA).  There was, 
however, no significant difference in the proportion of activated microglia between the 4-16 
week time-points (figure 3.3).  
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Figure 3.3: Top panel: Microglial activation expressed as a percent of total microglia in the 
hypothalamic paraventricular nucleus. Bottom panel: Total number of microglia (activated + 
non-activated) in the same region is shown in the bottom panel.  Counting was performed in 
the areas outlined in figure 3.1. Data were obtained from non-operated (N = 12), sham 
animals (N = 17) and in rats at 24 hours (N = 4), and 1, 4, 8, 12 and 16 weeks (N = 6, 3, 4, 3, 
5 respectively) after myocardial infarction. Values are expressed as the mean ± SEM. * 
P<0.001 compared to sham 
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Infarct Size, Activation of Microglia and Lung weight  
There was no significant difference in the size of the infarcts between the different time 
points following the myocardial infarction; the myocardial infarct size averaged between 27 - 
48% of the ventricular circumference (Figure 3.4).  Comparison of the infarct size to the 
proportion of activated microglia in all animals that underwent myocardial infarction did not 
show any correlation (figure 3.4)  
 
There was a significant difference overall in the lung weights (One way ANOVA, P<0.01). 
However, comparison of the individual means to the sham group (1.55 + 0.07 g) did not 
detect a statistically significant difference (1.68 + 0.06g, 16 weeks post myocardial 
infarction). 
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Figure 3.4: Top panel: Infarct size expressed as a percentage of ventricular circumference in 
rats at 24 hours (N = 4), and 1, 4, 8, 12 and 16 weeks (N = 6, 3, 4, 3, 5 respectively) after 
myocardial infarction. Values are expressed as the mean ± SEM.  Bottom panel: Infarct size 
expressed as a percentage of ventricular circumference correlated to percent of microglia 
activated in the hypothalamic paraventricular nucleus 24 hours and 1-16 weeks following 
myocardial infarction.  
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Ventricular function 
Echocardiography 
Compared to sham animals, ejection fractions were significantly lower following myocardial 
infarction compared to that observed in the sham group (F(6,39) = 19.84, P<0.0001, One-
Way ANOVA) (Figure 3.5).  Twelve to sixteen weeks following myocardial infarction, 
ejection fractions were between 30-44%, with only 3 rats above 37.5%, indicating severely 
reduced left ventricular function. There was no correlation, however, between the ejection 
fraction and the proportion of microglia activated (Figure 3.5). Similarly, percent fractional 
shortening was significantly reduced following myocardial infarction (F(6,39) = 12.89, 
P<0.0001, One-Way ANOVA) (Figure 3.5).  There was no correlation between the fractional 
shortening and the proportion of microglia activated (Figure 3.5).  Table 1 shows the left 
ventricular internal diameter in systole and diastole, posterior wall thickness in diastole and 
also the interventricular septal thickness in diastole in all groups of animals. Post Hoc 
statistical analysis showed there were significant differences from sham animals in left 
ventricular internal diameter in systole, at 8-12 weeks, and diastole, at 12 and 16, weeks 
following myocardial infarction (Table 3.1).  Compared to shams, the interventricular septal 
thickness in diastole was reduced significantly at 1, 4, 12, and 16 week time points following 
myocardial infarction (Table 3.1). 
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Figure 3.5: Top panel: Percent ejection fraction and fractional shortening determined from 
echocardiography analysis in non-operated (N = 12), sham rats (N=12) and in rats at 1, 4, 8, 
12 and 16 weeks (N = 6, 3, 4, 3, 5 respectively) after myocardial infarction. Values are 
expressed as the mean ± SEM.  * P<0.05, **P<0.01, *** P<0.001 compared to sham. Bottom 
panel: Percent ejection fraction and fractional shortening correlated to percent of microglia 
activated in the hypothalamic paraventricular nucleus 1-16 weeks following myocardial 
infarction 
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Table 3.1: Echocardiography parameters from sham animals, non-operated animals and in animals 1 to 16 weeks following myocardial 
infarction (MI), describing left ventricular internal diameter in systole and diastole, interventricular septal thickness and left ventricular posterior 
wall thickness in diastole (d). 
 
Sham 
(N=12) 
Non-operated  
(N=12) 
MI – 1 week  
(N=6) 
MI – 4 week  
(N=3) 
 
MI – 8 weeks  
(N=4) 
MI – 12 weeks  
(N=3) 
 
MI – 16 weeks 
(N=5) 
Left Ventricular Internal 
Diameter in diastole – 
LVIDd (mm) 
9.08±0.29 8.88±0.21 8.51±0.30 10.12±0.50 10.27±0.67 12.00±0.82*** 11.85±0.40*** 
Left Ventricular Internal 
Diameter in systole – 
LVIDs (mm) 
5.38±0.37 5.03±0.25 6.68±0.32 7.50±1.02 7.39±0.85* 9.46±1.09*** 10.31±0.32*** 
Interventricular Septal 
Thickness in diastole – 
IVSd (mm) 
1.47±0.06 1.37±0.04 1.06±0.06* 0.79±0.24** 1.26±0.25 0.83±0.22** 0.70±0.11*** 
LV Posterior  Wall 
Thickness in diastole – 
LVPWd (mm)) 
1.63±0.08 1.47±0.05 1.59±0.08 1.50±0.04 1.75±0.20 1.57±0.08 1.50±0.05 
 
* P<0.05, ** P<0.01, ***P<0.001 compared to Sham, post hoc using Dunnet’s test.  
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Hemodynamic measurements 
Left ventricular end diastolic pressure was significantly elevated at 4-16 weeks following 
myocardial infarction compared to the level observed in the sham group (Table 3.1), and left 
ventricular contractility (dP/dt max) was significantly reduced at 16 weeks following 
myocardial infarction compared to shams (Table 3.2).  There was no significant correlation 
between the hemodynamic variables and the proportion of activated microglia. 
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Table 3.2: Haemodynamic variables from sham animals, non-operated animals and in animals 1 to 16 weeks following myocardial infarction 
(MI), describing left ventricular end-diastolic pressure and dP/dt max. 
 
 Sham 
(N=12) 
Non-
operated  
(N=12) 
MI – 1 week  
(N=6) 
MI – 4 week  
(N=3) 
 
MI – 8 week  
(N=4) 
 
MI – 12 week  
(N=3) 
 
MI – 16 week 
(N=5) 
Left Ventricular 
End Diastolic 
Pressure 
(mmHg) 
3.84±0.4
2 3.21±0..53 4.85±0.26 8.29±1.52** 12.08±0.73** 8.45±0.76** 6.07±0.26* 
Left Ventricular 
Dp/dt max 
(mmHg/s) 
5450±15
2 5484±135 5017±245 4521±331 4328±449 4216±444 4028±247* 
 
* P<0.01, ** P<0.001 compared to Sham, post hoc using Dunnet’s test.  
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Section 3.4: Discussion 
 
The present work shows that following myocardial infarction, activation of microglia was not 
observed in the PVN of the hypothalamus within the first week after the infarct.  In contrast 4 
weeks following the infarction, activated microglia were observed in the PVN and there was 
a sustained activation lasting at least 16 weeks after myocardial infarction.  
 
In the present study the activation of microglia was not observed at 24 hrs and 1 week 
following myocardial infarction.  Furthermore, the activation was specific to the PVN as 
adjacent areas in the hypothalamus did not show activated microglia (data not shown), 
confirming earlier observations (Rana et al., 2010). Previously, the only time points 
monitored were 2 and 5 weeks after the myocardial infarct, where it was shown that 
microglia were activated at both time-points (Rana et al., 2010).  Taken together, the 
evidence suggests that activated microglia can be observed between 1-2 weeks following 
myocardial infarction.  
 
Upon activation, microglia synthesize and secrete cytokines (Colton and Gilbert, 1987, 
Sawada et al., 1989, Mizuno et al., 1994, Suzumura et al., 1996, Frucht et al., 2001, Mizuno 
et al., 2003), and therefore could contribute to the increased levels of cytokines detected in 
the PVN following myocardial infarction.  The findings in the present report, however, do not 
provide evidence for microglia playing an important role in the production of cytokines 
within the first week after myocardial infarction. Since cytokine levels in the PVN are 
elevated within 30 minutes of a myocardial infarct (Felder et al., 2003, Francis et al., 2004a, 
Francis et al., 2004b, Kang et al., 2008), other factors are likely to be the major contributors 
to the initial elevation of cytokines. These mechanisms could include (i) pro-inflammatory 
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cytokines which are released into the bloodstream by the damaged heart and induce PGE2 
production in endothelial cells in the cerebral blood vessels (Felder et al., 2003, Zhang et al., 
2003, Francis et al., 2004a, Francis et al., 2004b), (ii) the activation of the renin-angiotensin-
aldosterone system, (Zhang et al., 2003) and (iii) increased production of reactive oxygen 
species (Lindley et al., 2004, Guggilam et al., 2007, Yu et al., 2008), all occur after a 
myocardial infarction and are known to induce cytokine release. 
 
In the present study there was activation of microglia in the PVN from 4 weeks following 
myocardial infarction and up to 16 weeks, which was the maximum period of observation in 
the present work. The findings indicate that after an initial delay there followed a sustained 
activation of microglia in the PVN induced by the  myocardial infarction. The results suggest 
that although microglia may not be involved in the initiation of the inflammatory response 
and the subsequent initial elevation of cytokines in the hypothalamus, it is likely that they 
contribute to the sustained inflammatory response in the PVN following a myocardial 
infarction.  
 
The inflammatory response in the PVN could also contribute to the increased neuronal 
activity that occurs within this brain nucleus following myocardial infarction (Zheng et al., 
2009, Kleiber et al., 2010). The PVN is a key regulator of renal sympathetic nerve activity 
(RSNA) (Badoer, 2010b), which is increased in chronic heart failure. Cytokines such as TNF-
α and IL-1 β injected into the PVN increase RSNA. Thus, our results support the possibility 
that activation of microglia in the PVN may contribute to the increased sympathetic nerve 
activity that is a characteristic of chronic heart failure through the local production of 
cytokines in the PVN (Francis et al., 2004a, Francis et al., 2004b, Guggilam et al., 2007, 
Helwig et al., 2007). 
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In the present study the degree of infarction was not correlated with the proportion of 
microglia activated. This suggests that the amount of cardiac damage following myocardial 
infarction does not influence the proportion of microglia activated.   
On average the ejection fraction declined with increasing time after myocardial infarction 
such that by week 12, most animals had severely reduced left ventricular function.  There was 
no correlation, however, between the proportion of microglia activated and ejection fraction, 
Furthermore, there was no correlation between fractional shortening and the proportion of 
microglia activated.  The results suggest that the degree of decline in cardiac function was not 
significantly affected by the proportion of microglia activated in the PVN.   
 
Additionally, we did not find a statistically significant increase in lung weights at any of the 
time points compared to the sham group (individual group comparisons).  We suspect that the 
size of the infarct together with the relatively small increases in left ventricular end diastolic 
pressure were not sufficient to cause statistically detectable increases in congestion in the 
lungs. 
 
In conclusion, microglia are activated in the hypothalamic PVN following myocardial 
infarction, but there is a delay of 1-2 weeks. After this time there is a significant increase in 
microglial activation that is sustained as cardiac function declines.  Activated microglia, 
therefore, may contribute to the chronic elevation in cytokine levels observed following 
myocardial infarction. Since cytokines elicit sympatho-excitatory effects when locally 
microinjected into the PVN, activated microglia may indirectly contribute to the mechanisms 
mediating the chronic increase in sympathetic nerve activity in animals with reduced left 
ventricular function induced following myocardial infarction.  
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Chapter 4: Attenuation of microglial and neuronal activation in the brain 
by icv minocycline following myocardial infarction 
 
Section 4.1: Introduction 
 
Following MI there are autonomic reflex responses which initially help support the heart but 
ultimately are detrimental and contribute to the progressive deterioration of cardiac function. 
A characteristic response seen following MI is a selective increase in sympathetic nerve 
activity to the heart, kidneys and skeletal muscle vasculature (Packer, 1988, Kaye et al., 1995, 
Mann, 1999). The mechanisms responsible for the increase in sympathetic drive are unclear, 
but there is good evidence that the PVN contributes (Felder et al., 2003, Francis et al., 2004a, 
Guggilam et al., 2007, Zheng et al., 2009, Badoer, 2010b). Evidence suggests that an increase 
in pro-inflammatory cytokines in the PVN may play a key role in the elevation of 
sympathetic nerve activity observed following a myocardial infarction (Felder et al., 2003, 
Francis et al., 2004a, Francis et al., 2004b). For example, central administration of the pro-
inflammatory cytokine, TNF-α, elevates neuronal activity in the PVN and increases 
sympathetic nerve activity (Zhang et al., 2003) whereas blocking the actions of TNF-α in the 
PVN, can attenuate the neurohumoral activation seen in heart failure induced by myocardial 
infarction (Kang et al., 2008).  
 
Cytokines do not readily cross the blood brain barrier, therefore, local production in the brain 
is an important contributor to the increased levels of cytokines seen after MI (Felder et al., 
2003, Francis et al., 2004a, Francis et al., 2004b). One possible source of the endogenous 
cytokine production in the brain is microglial cells. Microglia are the resident immune cells 
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in the brain and are constantly sensing their environment in their ‘resting’ state (Nimmerjahn 
et al., 2005). In response to a stressful stimulus, microglia become activated and undergo 
dramatic morphological changes and secrete cytokines ((Streit et al., 1988, Streit and 
Kreutzberg, 1988, Nakajima and Kohsaka, 2001, Stence et al., 2001, Badoer, 2010a).  In a 
recent study, we found that microglia were activated in the PVN following a myocardial 
infarction but adjacent areas of the hypothalamus did not show such changes (Rana et al., 
2010).  
 
However many other areas within the brain are able to influence cardiovascular variables; 
these include the RVLM, PAG, NTS and AP. Although these areas are important in 
cardiovascular regulation it is not known whether microglia are activated in these areas 
following a myocardial infarction. One issue addressed by this study is to investigate whether 
these areas show any increased activation of microglia following a myocardial infarction 
similar to that seen in the PVN. 
 
Since cytokines administered into the hypothalamus increase sympathetic nerve activity, it 
would be expected that neuronal activity in that region would also be increased. In the PVN it 
has been known for some time that there is an increased neuronal activity following a 
myocardial infarction (Patel et al., 1993, Patel et al., 2000, Zhang et al., 2003). However, 
other brain regions involved in cardiovascular regulation have not been explored in detail. 
Thus, the second aim of the present study was to investigate whether neuronal activation 
occurred concomitantly in the same brain regions that showed microglial activation following 
a myocardial infarction. 
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The present study also investigated whether attenuation of microglial activation using 
minocycline would result in an attenuation of neuronal activity in the same regions and 
whether this would result in improved cardiac function. Minocycline is a tetracycline 
derivative with anti-inflammatory effects unrelated to its antimicrobial actions. Minocycline 
has also been shown to improve cardiac function following a myocardial infarction as it 
reduces inflammation in the heart and has been shown to reduce infarct size (Hang et al 2012, 
Romero-Perez et al 2008).   
 
Thus the aims of this study were; (i) to investigate inflammation in cardioregulatory areas of 
the brain in addition to the PVN, (ii) investigate whether microglial activation coincides with 
neuronal activation, (iii) investigate the effect of blocking microglial activation on neuronal 
activation, and (iv) determine if inhibiting microglial activation improves cardiac function 
 
Section 4.2: Materials and Methods 
 
Animal housing: 
 
Male SPF (Specific Pathogen Free) Sprague-Dawley rats obtained from the Animal Resource 
Centre (ARC, Western Australia, Australia) were used in these studies. The animals were 
housed in a temperature-controlled room on a 12:12 hour light/dark cycle, in the Animal 
Facility (RMIT University, Victoria, Australia), where rat chow and tap water were available 
ad libitum. The animals were held for a minimum period of one week prior to undergoing any 
experimental procedure. All experimental protocols used in this study were performed in 
accordance with the Prevention of Cruelty to Animals Act, Australia 1986, conformed to the 
guidelines set out by the National Health and Medical Research Council of Australia (2007) 
and the Guide for the Care and Use of Laboratory Animals published by the United States 
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National Institutes of Health. The protocols and procedures were approved by the RMIT 
University animal ethics committee. 
 
Experimental Protocol: 
All experiments were performed under general anaesthesia (3% isoflurane in 97% oxygen). 
Animals were implanted with a subcutaneous osmotic pump connected to a cannula for direct 
infusion of either 0.9% saline or minocycline (172ng/ml, 0.3µl/hr) into the lateral ventricle of 
the brain as described in chapter 2. After a one week recovery period the animals then 
underwent either a myocardial infarction via a ligation of the left anterior descending 
coronary artery or sham procedure where the artery was not ligated as described in chapter 2.  
Animals were divided into the following treatment groups:  saline infusion and MI (n=3), 
minocycline infusion and MI (n=5), minocycline infusion and sham operation (n=3) and 
control animals (n=8). This latter group consisted of rats that had undergone a sham operation 
and had a saline infusion (n=3) and rats which did not have any surgical procedures 
performed (n=5). The animals were placed in the same group as no differences were seen 
between them. 
 
Echocardiography was performed prior to MI or sham operation and at 12 weeks post MI. 
Every 4 weeks the osmotic mini-pumps were changed. This was performed by anaesthetising 
the animals (3% isoflurane in 97% oxygen) and making a small incision in between the 
shoulder blades. The old pump was discarded and a new pump with the same concentration 
of either saline or minocycline was connected to the cannula. At 12 weeks post MI the 
animals underwent an echocardiography and were then given an overdose of pentobarbitone 
150mg/kg, i.v (Lethabarb, Virbac Animal Health Pty Ltd., NSW, Australia). 
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Tissue Collection: 
The brain was collected and placed in fresh 10% neutral buffered formalin (NBF) for 4hours 
followed by 30% sucrose and kept at 4⁰C until sectioning. The heart and lungs were collected 
and weighed, the left ventricle was subsequently placed in 10% NBF for 4 hours then into 
30% sucrose until sectioning to determine infarct size. The left ventricle was stained with a 
standard hematoxylin and eosin stain. Infarct sizes were determined by expressing the 
damaged epicardial and luminal surfaces as a percentage of total circumference. The brain 
was collected, cut and the sections were processed using immunohistochemistry to detect 
CD11b (OX-42 clone) and FRA as described in chapter 2. 
 
Immunohistochemistry analysis for CD11b (clone OX-42) 
Morphological analysis and quantification of microglia was performed with a light 
microscope using 400 times magnification. Three rostral-caudal levels of the PVN, four 
rostral-caudal levels of the PAG, three different sections of the RVLM at approximately the 
same rostral-caudal level , three rostral-caudal levels of the NTS and one rostral-caudal level 
of the AP were examined. The total number of microglia was counted in two squares 
measuring 0.2 x 0.2mm in size (figure). The numbers of activated microglia (see methods 
section for definition of activated microglia) were expressed as a percentage of the total 
number of microglia counted. Due to the difference in the number of sections counted in each 
nucleus the number of microglia were averaged per section. Analysis was performed 
unilaterally by a single observer blinded to the treatment.    
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Immunohistochemistry analysis for FRA 
To identify increased neuronal activation, immunohistochemistry to detect FRA proteins was 
performed. This was performed in the same manner as the analysis for CD11b (clone OX-42) 
With the number of FRA positive cell nuclei counted in two squares counted of the PVN, 
PAG, RVLM, NTS and AP recorded.  
 
Section 4.3: Results 
 
Activation of Microglia and Neurons 
PVN  
In the PVN of control animals there was very little microglial activation (approximately 10%) 
(Fig 4.1). The proportion of activated microglia increased dramatically following a 
myocardial infarction (fig 4.1), and this was observed across all rostro-caudal levels of the 
PVN. Treatment with icv minocycline, reduced the proportion of activated microglia by 
approximately 50% across all levels of the PVN in myocardial infarcted animals (fig 4.1). 
Minocycline administration alone (with a sham operation) did not affect the proportion of 
activated microglia compared to control animals (fig 4.1). The total numbers of microglia 
counted in the PVN of the different treatment groups was similar (fig 4.1). In the area 
adjacent to the PVN there was no significant increase in the proportion of activated microglia 
except for the rostral level of the PVN where there was a small but statistically significant 
increase in the minocycline treated myocardial infarcted animals (Fig 4.1).  
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FRA-positive cell nuclei significantly increased following a myocardial infarction compared 
to control animals in all levels of the PVN examined (fig 4.1). Minocycline treatment 
significantly reduced this response at the mid and caudal levels of the PVN (fig 4.1). 
Minocycline alone had no significant effect on the number of FRA-positive cell nuclei. 
Adjacent to the PVN there was a small but significant increase in the number of FRA-
positive cell nuclei in the rostral PVN following a myocardial infarction compared to control 
(fig 4.1). There was no significant difference in the FRA-positive nuclei numbers at any other 
level following any other treatment.  
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Figure 4.1: Top panel: Microglial activation expressed as a percent of total microglia in the 
PVN or adjacent to it (rostral -1.4mm from bregma, mid -1.8mm from bregma, and caudal -
2.0mm from bregma). Middle panel: Total number of microglia (activated + non-activated) in 
the same regions. Bottom: Fos Related Antigen (FRA)-positive cell nuclei representing 
activated neurons in the same regions as the counts for microglia. Values are expressed as the 
mean ± SEM. *P<0.05, *** P<0.001 compared to controls; ## P<0.01, ‡‡‡P<0.001 
compared to a myocardial infarction. 
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PAG 
A myocardial infarction significantly increased activated microglia within the dorsomedial, 
lateral, dorsolateral and ventrolateral subnuclei of the PAG compared to controls (Fig 4.2). 
Minocycline treatment attenuated this increase in activation by approximately 50% in all 
subnuclei of the PAG (Fig 4.2). The total number of microglia counted per section was 
similar in all subnuclei of the PAG (Fig 4.2). In the area adjacent to the PAG there was a 
small but significant increase in activated microglia compared to controls in all of the groups 
examined (Fig 4.2).  
Following a myocardial infarction, the number of FRA-positive cell nuclei increased 
significantly throughout the PAG and was particularly prominent in the ventrolateral PAG. 
Minocycline treatment in myocardial infarcted animals virtually abolished the increase in 
FRA-positive cell nuclei in the dorsomedial, lateral and ventrolateral PAG but there was no 
effect of minocycline treatment in the dorsolateral PAG (fig 4.2). Minocycline alone had no 
effect on the number of FRA-positive cell nuclei within the different subnuclei of the PAG. 
In the area adjacent to the PAG there was no signifcant increase in FRA- positive cell nuclei 
between the different groups (fig 4.2). 
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Figure 4.2: Top panel: Microglial activation expressed as a percent of total microglia in the 
subnuclei of the periaqueductal gray (PAG) or adjacent to it. Middle panel: Total number of 
microglia (activated + non-activated) in the same region. Bottom: Fos Related Antigen 
(FRA)-positive cell nuclei representing activated neurons in the same regions as the counts 
for microglia. Values are expressed as the mean ± SEM. *P<0.05, **P<0.01, *** P<0.001 
compared to controls; ‡P<0.05, ‡‡ P<0.01, ‡‡‡P<0.001 compared to MI. 
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Rostral Ventrolateral Medulla (RVLM) 
Within the RVLM, there was a significant increase in activated microglia following a 
myocardial infarction compared to the controls and this was significantly attenuated by 
minocycline treatment by over 50% (figure 4.3). In the area adjacent to the RVLM, there was 
a small significant increase in activated microglia following a myocardial infarction and this 
was not markedly affected by pretreatment with minocycline (figure 4.3). The total number 
of microglia per section counted were similar in each of the treatment groups. 
 
The numbers of FRA-positive cell nuclei were significantly increased following a myocardial 
infarction in the RVLM (figure 4.3). Minocycline treatment abolished the increase seen with 
myocardial infarction alone. (figure 4.3) In the areas adjacent to the RVLM there was no 
significant increase in the FRA-positive cell nuclei (figure 4.3). 
 
Nucleus Tractus Solitarius (NTS), Area Postrema (AP) 
Within the NTS and area postrema there was a significant increase in activated microglia 
following a myocardial infarction compared to the respective controls. This was significantly 
attenuated with minocycline treatment in the NTS by over 50%, but not the AP (figure 4.3). 
In the area adjacent to the NTS/AP there was a small increase in activated microglia 
following a myocardial infarction but this only attained statistical significance in the 
myocardial inarcted group treated with minocycline (figure 4.3).  
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In the NTS, the numbers of FRA-positive cell nuclei were significantly increased by 
approximately 30% following a myocardial infarction but there was no significant increase in 
the AP compared to controls (figure 4.3). Minocycline treatment virtually abolished the 
increase in the NTS seen with myocardial infarction alone. However, within the AP there was 
a significantly greater increase in the number of FRA-positive cell nuclei following a 
myocardial infarction in the group pretreated with minocycline compared to the control group 
(figure 4.3).  In the areas adjacent to the RVLM, and to the NTS/AP there were no significant 
increases in the number of FRA-positive cell nuclei (figure 4.3).  
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Figure 4.3: Top panel: Microglial activation expressed as a percent of total microglia in the 
rostral ventrolateral medulla (RVLM) or adjacent to it, in the nucleus tractus solitarius (NTS) 
and in the  area postrema (AP). Middle panel: Total number of microglia (activated + non-
activated) in the same regions. Bottom: Fos Related Antigen (FRA)-positive cell nuclei 
representing activated neurons in the same regions as the counts for microglia. Values are 
expressed as the mean ± SEM. *P<0.05, **P<0.01, *** P<0.001 compared to controls; ‡‡ 
P<0.01, ‡‡‡P<0.001 compared to MI. 
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Infact Size and Cardiac Function 
The myocardial infarction produced an average infarct size of 22±4%. Compared to controls, 
the percent fractional shortening was significantly reduced following the myocardial 
infarction (Table 4.1). Pretreatment with minocycline did not ameliorate the reduction in 
percent fractional shortening induced by the myocardial infarction (Table 4.1). 
Echocardiography measurements showed that myocardial infarction significantly reduced left 
ventricular internal diameter in systole and diastole and the interventricular septal thickness 
in diastole and systole, but no significant differences in posterior wall thickness compared to 
controls (Table 4.1). 
 
Tissue Weights 
The average body weight of animals was similar across all treatment groups. Similarly there 
were no significant differences in heart, lung, atrial, left ventricular or right ventricular 
weights observed between groups (Table 4.2).  
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Table 4.1: 
Echocardiography measurements at 12 weeks for controls (non-myocardial infarcted) (N=8), minocycline treated (non-myocardial infarcted) (N 
= 3), myocardial infarcted (MI) (N=3) and in MI rats treated with minocycline intracerebroventricularly (N = 5). Abbreviations: IVSd, 
interventricular septum thickness in diastole; IVSs, interventricular septum thickness in systole; LVIDd, left ventricular internal diameter in 
diastole; LVIDs, left ventricular internal diameter in systole; LVPWd, left ventricular posterior wall thickness in diastole; LVPWs, left 
ventricular posterior wall thickness in systole; %FS, percent fractional shortening. Data are expressed as mean±SEM. * indicates P<0.05, 
***P<0.001 and**** P<0.0001 compared to control animals. ## indicates P<0.01 and ### P<0.001 compared to MI +Vehicle animals. 
 
 
Group IVSd (cm) IVSs (cm) LVIDd (cm) LVIDs (cm) LVPWd (cm) LVPWs (cm) %FS (%) 
Control 0.16±0.01 0.26±0.01 0.76±0.02 0.45±0.02 0.20±0.01 0.27±0.01 41.00±1.71 
Minocycline 0.18±0.01 0.290±0.02 0.80±0.01 0.45±0.04 0.26±0.04 0.32±0.02 43.31±4.22 
MI 0.11±0.01* 0.12±0.03*** 0.84±0.05 0.69±0.08*** 0.23±0.03 0.29±0.03 18.40±5.60*** 
Minocycline 
+ MI 0.11±0.01* 0.11±0.01**** 1.09±0.02****### 0.93±0.03****## 0.19±0.01 0.24±0.02 14.37±1.16**** 
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Table 4.2: Tissue and body weights at 12 weeks for controls (non-myocardial infarcted) (N=8), minocycline treated (non-myocardial infarcted) 
(N = 3), myocardial infarcted (N=3) and in MI rats treated with minocycline intracerebroventricularly (N = 5). Abbreviations: RV, right 
ventricle; LV, left ventricle 
 
Group Body weight (g) Atria Wt (g) RV Wt (g) LV Wt(g) Heart Wt (g) Lung Wt (g) 
Control 547.38 ± 10.79 0.09±0.01 0.28 ± 0.01 1.16 ± 0.06 1.53 ± 0.06 2.43 ± 0.29 
Minocycline 585 ± 35.47 0.12 ± 0.02 0.3 ± 0.04 1.10 ± 0.22 1.53 ± 0.26 3.27 ± 0.52 
MI 588.33 ± 10.84 0.12 ± 0.01 0.35 ± 0.01 1.22 ± 0.07 1.69 ± 0.07 2.58 ± 0.32 
MI + Minocycline 575.8 ±33.74 0.09 ± 0.01 0.29 ± 0.04 1.13 ± 0.05 1.52 ± 0.09 2.37 ± 0.17 
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Section 4.4: Discussion 
 
The present study showed a myocardial infarction induces activation of microglia in the 
PVN, PAG, RVLM, NTS and AP. In all of these areas except for the AP this was 
accompanied by an increase in neuronal activation as determined by the increase in cells with 
elevated FRA proteins. Areas immediately adjacent to the nuclei examined did not show such 
marked microglial or neuronal activation. The increased microglial and neuronal activation in 
all areas except for the AP was able to be attenuated with minocycline treatment. 
Minocycline is a tetracycline derivative with anti-inflammatory effects unrelated to its 
antimicrobial actions, and has be used to reduce inflammation following cerebral ischemia 
(Yrjanheikki et al 1999, He et al 2001). 
PVN: 
In the PVN there was an increase in both microglial and neuronal activation following a 
myocardial infarction in the PVN. This confirms previous studies showing increases in 
microglial activity (Rana et al) and neuronal activity (Patel et al 1993, Vahid-Ansari and 
Leenen 1998) following a myocardial infarction within the PVN.  The microglial activation 
was relatively selective within the PVN as the area adjacent to the PVN had no such 
response, in agreement with previous work (Rana et al 2010, Dworak et al 2012). 
Administration of minocycline was able to attenuate the increase in microglial activation by 
over 50% indicating that microglial activation could be markedly attenuated by central 
infusion of minocycline.  
 
There was also increased neuronal activity within the PVN following myocardial infarction 
as indicated by the increase in FRA-positive cell nuclei observed in the present study. The 
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finding that minocycline treatment also attenuated this response suggests that the increase in 
neuronal activity is related to increased microglial activation. Furthermore, adjacent to the 
PVN, there was no increase in neuronal activation further supporting the view that the 
neuronal activation was a result of microglial activation. 
PAG: 
In the present study myocardial infarction induced microglial activation in the lateral, 
dorsolateral and ventrolateral subnuclei of the periaqueductal gray, and these responses were 
attenuated markedly by minocycline treatment.  The number of FRA-positive cell nuclei was 
increased in the periaqueductal gray following MI and this was particularly prominent in the 
ventrolateral periaqueductal gray. Minocycline virtually abolished the increase in FRA-
positive cell nuclei except in the dorsolateral periaqueductal gray.  It should be noted, 
however, that the number of FRA-positive cell nuclei in that subnucleus was similar to that 
observed in the group treated with minocycline but without MI. 
 
The periaqueductal gray has not been investigated previously with respect to myocardial 
infarction. It is well known for its influence in pain, stress and physiological and behavioural 
responses to threatening situations  (Carrive, 1993, Walker and Carrive, 2003). With respect 
to cardiovascular effects, the periaqueductal gray contributes to pressor and depressor 
responses involving changes in sympathetic nerve activity (Benarroch, 2012). The lateral and 
dorsolateral periaqueductal gray mediate the sympatho-excitatory responses, and the 
ventrolateral periaqueductal gray mediates the sympatho-inhibitory responses. 
Activation of neurons in the sympatho-excitatory dorsolateral and lateral periaqueductal gray 
is in agreement with an increased sympathetic nerve activity to the heart in response to a 
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stressor stimulus and to that observed following left ventricular dysfunction (Kaye et al., 
1995). By contrast, neuronal activation in the sympatho-inhibitory ventrolateral 
periaqueductal gray suggests this area could counteract the elevated sympathetic nerve 
activity observed following left ventricular dysfunction. Thus, further investigation is 
required. 
 
Immediately adjacent to the periaqueductal gray there was no increase in the number of FRA-
positive cell nuclei, although there was a small increase in the number of activated microglia 
which was not affected by minocycline treatment. The significance of this increased 
microglial activation is not clear since it was also observed in the minocycline treated group 
that did not have a myocardial infarction. Nonetheless, the amount of activation within the 
periaqueductal gray compared to the region immediately adjacent to it suggests a degree of 
selectivity. It is also possible that the activation in adjacent areas may reflect intense 
activation within the brain nucleus that spreads to immediately adjacent areas.  
 
 
Medulla: 
There was an increase in microglial activation and FRA-positive cell nuclei in the rostral 
ventrolateral medulla. This critical brain nucleus involved in sympathetic tone and blood 
pressure regulation is a key regulator of sympathetic nerve activity to the heart and kidneys 
(McAllen and May, 1994) and activation of neurons in this region supports a role for the 
rostral ventrolateral medulla in the elevation of sympathetic tone following left ventricular 
dysfunction.  Attenuation of the activation of microglia and of the increased neuronal activity 
by minocycline suggests that the increased neuronal activity is a result of the inflammatory 
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response observed. A threshold level of inflammation may need to be reached in the rostral 
ventrolateral medulla to increase neuronal activity since (i) minocycline attenuated the 
increase in microglial activation but prevented the increase in neuronal activity within the 
region, and (ii) the area immediately adjacent to the rostral ventrolateral medulla showed 
weak but significantly increased activation of microglia that was not accompanied by an 
increase in FRA-positive cell nuclei. 
 
The present findings in the rostral ventrolateral medulla are in agreement with previous 
reports showing that in chronic heart failure there is overactivity in the rostral ventrolateral 
medulla (Zhang et al., 2003, Gao et al., 2010). Recent work suggests a key role of angiotensin 
II type 1 receptors whose over-expression in the rostral ventrolateral medulla could contribute 
to increased production of reactive oxygen species and pro-inflammatory cytokines and the 
resultant sympatho-excitation (Gao et al., 2010). 
In the dorsomedial medulla, the nucleus tractus solitarius showed an increase in microglial 
and neuronal activation after myocardial infarction. Minocycline treatment significantly 
attenuated microglial activation and prevented the increase in neuronal activation. Activation 
of the microglia has also been observed following damage to the vagus nerve and 
minocycline has been found to attenuate the response (Gallaher et al., 2012). Given the 
nucleus tractus solitarius is the site of the termination of the primary cardiovascular afferents, 
the activation of neurons could be expected 
 
The nucleus tractus solitarius is a key integrative nucleus involved in regulating arterial 
pressure and sympathetic nerve activity. The effects of cytokines locally in the nucleus 
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tractus solitarius on sympathetic nerve activity have not  been studied, however, actions of 
cytokines on synaptic function within the nucleus tractus solitarius and changes in blood 
pressure following local administration of some cytokines suggests such an action. The 
nature of the effect, however, depends on the cytokine, as shown by the observation that a 
reduction in blood pressure occurs following interleukin 1, but not following tumor necrosis 
factor alpha administration into the nucleus tractus solitarius (Mollace et al., 2001). 
 
In the area postrema, following myocardial infarction there was a significant increase in 
microglial activation, which was not significantly attenuated by minocycline. The area 
postrema lacks a blood brain barrier allowing circulating pro-inflammatory cytokines greater 
access to microglia and neurons than in the other nuclei examined in this study. This could 
contribute to the activation of microglia observed, and may also contribute to the lack of 
effect of minocycline since the low dose used may simply have been incapable of inhibiting 
the actions of the many circulating factors that may access the area postrema. Following 
myocardial infarction , there was no significant increase in the number of FRA-positive cell 
nuclei in the area postrema.  However, in the myocardial infarcted group treated with 
minocycline, there was a significant increase in the number of FRA-positive cell nuclei.  The 
reason for this is unclear but may be related to the unique environment of the area postrema.  
 
Minocycline 
Although minocycline was able to reduce the activation of microglia and neuronal activation 
in the nuclei other than the area postrema, minocycline did not ameliorate the reduction in 
heart function observed following the myocardial infarction. This suggests that attenuating 
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microglial activation may not be sufficient to improve heart function. Several studies have 
found that antagonism of pro-inflammatory cytokines in the brain may slightly improve 
cardiac function, although reductions in percent fractional shortening or ejection fraction 
were still 50-60% lower than in non-treated controls (Guggilam et al., 2007, Kang et al., 
2008). Nonetheless, autonomic dysfunction such as the increase in sympathetic nerve activity 
observed following myocardial infarction was markedly improved in those animals in which 
cytokine synthesis was inhibited in the PVN (Guggilam et al., 2007, Kang et al., 2008). 
Taken together, these results suggest that inflammation in the brain nuclei examined may be 
more involved in autonomic dysfunction rather than the progressive reduction in cardiac 
function.  However, other studies have shown marked improvement in cardiac function 
following manipulation of reactive oxygen species production in the brain of rats with 
myocardial infarction –induced heart failure (Lindley et al., 2009, Infanger et al., 2010). 
 
It should be noted, that in the present study the average size of the infarction was 22%. 
Despite the smaller infarct size, marked activation of microglia was observed in the PVN, 
similar to that previously observed with larger infarcts (Rana et al., 2010, Dworak et al., 
2012). This suggests that damage to the heart does not need to be very extensive to elicit 
inflammatory responses in the brain.  The findings suggest that further work on defining the 
correlation between the degree of heart damage and inflammation in the brain is worthwhile. 
 
Summary: 
In conclusion, myocardial infarction elicited microglial activation in key cardiovascular 
regulatory nuclei. There was a concomitant increase in neuronal activation in those brain 
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nuclei. Inhibition of the activation of microglia attenuated the increased neuronal activation 
suggesting inflammation in the brain following myocardial infarction activates neurons in 
specific cardiovascular regulatory nuclei. This could contribute to the peripheral autonomic 
dysfunction observed following a heart attack but requires further investigation. 
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Chapter 5: Discussion 
 
This work investigated; (i) the time course for the activation of microglia following 
myocardial infarction, (ii) microglial activation within key brain regions following a 
myocardial infarction, (iii) neuronal activation following a myocardial infarction in regions 
where microglia become activated, and (iv) whether blocking microglial activation influences 
neuronal activation and cardiac function. Each of these will be discussed in this chapter. 
 
Time course of activated microglia 
The present work suggests that microglial activation occurred within the PVN between 1 and 
2 weeks post myocardial infarction. No activation was found at one week post myocardial 
infarction in the present study and previous work has shown microglial activation occurred 2 
weeks post myocardial infarction (Rana et al., 2010). This suggests that microglia may not be 
the initial source of cytokine production in the hypothalamus that has previously been 
observed, with levels of cytokines being elevated within 30 minutes of a myocardial 
infarction (Francis et al., 2004a). However microglia may still be contributing to the 
maintained cytokine production following a myocardial infarction as a found a greater level 
of elevated cytokines 4 weeks post myocardial infarction compared to other time points 
(Francis et al., 2004a). The present study is in agreement with this since it was found that 
microglial activation was sustained for the 16 week observation period. Taken together, the 
evidence suggests the initial increase in cytokines may be triggering microglial activation and 
this then leads to a self perpetuating cycle. Future studies aimed at investigating how 
cytokines are initially produced within the brain, and whether they trigger microglial 
activation and increased neuronal activity, would be important in this regard. 
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Activated microglia in the brain nuclei involved in cardiovascular regulation 
The present work demonstrates that microglial activation occurs in many autonomic nuclei of 
the brain involved in cardiovascular regulation, not just the PVN. These include the RVLM, 
NTS, AP and PAG. The increased microglial activation was not observed in regions adjacent 
to those nuclei suggesting that there is site specificity. Given the role these nuclei play in 
regulating sympathetic nerve activity, heart rate and blood pressure, the data suggests that 
localised inflammation may be playing a role in the autonomic dysfunction seen following 
myocardial infarction. Future studies to investigate the correlation between sympathetic nerve 
activity and microglia activation in the specific nuclei examined in myocardial induced heart 
failure will be worthwhile. 
 
Neuronal activation following myocardial infarction 
In the present study there was increased neuronal activity found in the PVN, PAG, RVLM 
and NTS. This increase in activity was also site specific as adjacent areas did not have 
increased neuronal activity. The increase in neuronal activity coincides with microglial 
activation. The increase in neuronal activity was associated with microglial activation; when 
microglial activation was blocked with minocycline, there was approximately a 50% 
reduction in the increased neuronal activation. This further supports the idea that activated 
microglia trigger an increase in cytokine production which in turn increases the neuronal 
activity and contributes to the autonomic dysfunction seen in heart failure. Future studies are 
needed to map other areas of the brain which may be involved in autonomic regulation for 
increased microglial and neuronal activity. Also future studies could include investigating the 
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effect of blocking microglial activation and, in turn reducing neuronal activation, on 
autonomic dysfunction. 
 
The effects of Minocycline 
 Microglia are targets for cytokines, as well as, producing cytokines when activated and are 
usually only activated for a short period of time. Sustained microglial activation could result 
in a long term increase in cytokines within the brain which may cause neurotoxicity. The 
mechanism by which cytokines cause autonomic dysfunction is unknown, this may occur 
though reactive oxygen species as NOX-4 levels within the PVN have been shown to be 
important for cardiac function post myocardial infarction (Infanger et al., 2010). It is 
therefore important to find ways of reducing cytokine production. When microglial activation 
was blocked with minocycline there was a reduction in increased neuronal activity suggesting 
a reduction in the production of cytokines following a myocardial infarction.  
 
In the present work, reducing microglial activation and neuronal activity did not produce an 
amelioration of cardiac function. This is in agreement with previous work which has shown 
either no improvement or slight improvement of cardiac function following reductions in 
cytokine synthesis (Guggilam et al., 2007, Kang et al., 2008). However in these studies 
sympathetic nerve activity was markedly improved when cytokine synthesis in the PVN was 
impaired (Guggilam et al., 2007, Kang et al., 2008). This suggests that inflammation in the 
brain nuclei may be more involved in autonomic dysfunction rather than the progressive 
reduction in cardiac function. Future studies could investigate the effects of minocycline on 
sympathetic nerve activity. 
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Concluding Statement 
Microglia may play a role in the autonomic dysfunction seen following a myocardial 
infarction. This research has demonstrated that: (i) microglial activation likely follows 
cytokine production in the brain, (ii) microglial activation following a myocardial infarction 
is specifically increased within key cardioregulatory nuclei of the brain, (iii) increased 
neuronal activity coincides with microglial activation within key cardioregulatory nuclei of 
the brain, and (iv) inhibiting microglial activation is able to reduce the increased neuronal 
activity. 
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